CA2262384A1 - Compositions and methods for intervertebral disc reformation - Google Patents
Compositions and methods for intervertebral disc reformation Download PDFInfo
- Publication number
- CA2262384A1 CA2262384A1 CA002262384A CA2262384A CA2262384A1 CA 2262384 A1 CA2262384 A1 CA 2262384A1 CA 002262384 A CA002262384 A CA 002262384A CA 2262384 A CA2262384 A CA 2262384A CA 2262384 A1 CA2262384 A1 CA 2262384A1
- Authority
- CA
- Canada
- Prior art keywords
- substrate
- bioactive
- cells
- intervertebral disc
- polymer foam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3817—Cartilage-forming cells, e.g. pre-chondrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/44—Joints for the spine, e.g. vertebrae, spinal discs
- A61F2/442—Intervertebral or spinal discs, e.g. resilient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/025—Other specific inorganic materials not covered by A61L27/04 - A61L27/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/30—Inorganic materials
- A61L27/306—Other specific inorganic materials not covered by A61L27/303 - A61L27/32
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
- A61L27/3852—Cartilage, e.g. meniscus
- A61L27/3856—Intervertebral discs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30108—Shapes
- A61F2002/3011—Cross-sections or two-dimensional shapes
- A61F2002/30182—Other shapes
- A61F2002/30187—D-shaped or half-disc-shaped
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0028—Shapes in the form of latin or greek characters
- A61F2230/0034—D-shaped
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/38—Materials or treatment for tissue regeneration for reconstruction of the spine, vertebrae or intervertebral discs
Abstract
Methods of reforming degenerated intervertebral discs are provided in accordance with methods of the invention. Hybrid materials useful in methods of the present invention are also provided.
Description
W098/05274 PCT~S97/13854 COMPOSITIONS AND METHODS FOR INTERv~Kl~RAL DISC REFORMATION
FIELD OF THE lNv~NllON
The present invention concerns methods and materials useful for reforming degenerated discs of the spine of a vertebrate and in particular the spine of a human.
BACKGROUND OF THE lNv~~ lON
Back pain is one of the most frequently reported musculoskeletal problems in the United States. 80~ of the adults will miss work at least three times in their career due to back pain. The most common factor causing low back pain is the degeneration of the disc. At the ages between 35 to 37, approximately a third of the US population have suffered from a herniated disc.
The main functions of the spine are to allow motion, transmit load and protect the neural elements. The vertebrae of the spine articulate with each other to allow motion in the frontal, sagittal and transverse planes. As the weight of the upper body increases, the vertebral bodies which are designed to sustain mainly compressive loads, increase in size caudally.
The intervertebral disc is a major link between the adjacent vertebrae of the spine. The intervertebral disc, the surrounding ligaments and muscles provide stability to the splne .
The intervertebral discs make up about 20-33~ of the lumbar spine length. They are capable of sustaining weight and transferring the load from one vertebral body to the next, as well as maintaining a deformable space to accommodate normal spine movement. Each disc consists of a gelatinous nucleus pulposus surrounded by a laminated, fibrous annulus fibrosus, situated between the end plates of the vertebrae above and below.
The nucleus pulposus contains collagen fibrils and water-binding glycosaminoglycans. At birth, the nucleus pulposus contains 88~ water, however, this percentage decreases with age. This water loss decreases its ability to withstand stress. The annulus fibrosus consists of fibrocartilaginous tissue and fibrous protein. The collagen fibers are arranged in between 10 to 20 lamellae which form concentric rings around the nucleus pulposus. The collagen fibers within each lamella are parallel to each other and runs at an angle of approximately 60 degrees from vertical. The direction of the inclination alternates with each lamellae. This crisscross arrangement enables the annulus fibrosus to withstand torsional and bending loads. The end-plates are composed of hyaline cartilage, and are directly connected to the lamellae which form the inner one-third of the annulus.
When under compressive loads, the nucleus pulposus flattens and bulges out radially. The annulus fibrosus stretches, resisting the stress. The end-plates of the vertebral body also resist the ability of the nucleus pulposus to deform. Thus, pressure is applied against the annulus and end-plate, transmitting the compressive loads to the vertebral body. When tensile forces are applied, the disc is raised to a certain height straining the collagen fibers in the annulus.
At bending, one side of the disc is in tension while the other side is in compression. The annulus of the compressed side bulges out.
, . . .
When the disc is subjected to torsion, there are shear stresses which vary proportionally to the distance from the axis of rotation, in the horizontal and axial plane. The layer of fibers oriented in the angle of motion is in tension while the fibers in the preceding or succeeding layer are relaxed. Similarly in sliding, the fibers oriented in the sliding direction are in tension while the fibers in the other layers relax.
Repeated rotational loading initiates circumferential tears in the annulus fibrosus, which gradually form radial tears into the nucleus pulposus until the nucleus degrades within the disc. In addition to the water loss which occurs with age, more water is also lost due to nucleus rupture, thereby reducing its ability to resist compressive loads. As such, the annulus bulges. As the severity of the tear increases, much of the contents of the disc is lost leaving a thin space of fibrous tissue. This condition is called disc resorption.
Increasing disc collapse can cause facet subluxation and stenosis of the intervertebral foramen. Subsequently, the degenerative process involves the facet joints equally. As the annulus bulges out posteriorly into the spinal canal, the nerve root may be compressed causing sciatica. Pain is felt from the lower back to the buttocks and the leg. Following the rupture of the disc, excessive motions such as excessive extension or flexion can occur, resulting in spine segmental instability. The spine is thus more vulnerable to trauma.
Herniation can occur due to disc degeneration or excessive load factors especially compression. Pain may result due to nerve root compression caused by protrusions.
The unstable phase of the degeneration progress allowing excessive movement may result in degenerative ~ spondylolisthesis, which is a breakdown of posterior joints.
The nerve is trapped between the inferior articular facet of the vertebrae above and the body of that below. Thus, sliding of a vertebral body on another damages the posterior joints due W098t05274 PCT~S97/13854 to fatigue and apply traction on the nerve root causing pain.
Surgical treatments for herniated disc include laminectomy, spinal fusion and disc replacement with protheses.
At this time, 150,000 spinal fusion procedures are performed per year in the US alone, and the numbers are growing exponentially. However, the results of spinal fusions are very varied. Some of the effects include non-unions, slow rate of fusion even with autografts, and significant frequency of morbidity at the graft donor site. In addition, even if the fusion is successful, joint motion is totally eliminated.
Adverse effects of spinal fusions have also been reported on adjacent unfused segments such as disc degeneration, herniation, instability spondylolysis and facet joint arthritis. A long-term follow-up of lower lumbar fusions in patients from 21 to 52 years of age found that 4~ of patients with spinal fusions were currently still experiencing low-back pain and 57~ had back pain within the previous year. 53~ of the patients tracked were on medication, 5~ had late sequela secondary surgery, 15~ had a repeat lumbar surgery, 42~ had symptoms of spinal stenosis, and 45~ had instability proximal to their fusion. This clinical data shows that significant long-term limitations are associated with spinal fusion.
An alternative to spinal fusion is the use of an intervertebral disc prosthesis. Ideally, a successful disc prosthesis will simulate the function of a normal disc. The disc replacement must be capable of sustaining weight and transferring load from one vertebral body to the next. It should be robust enough not to ~e injured during movement and should maintain a deformable space between the vertebral body to accommodate movement.
~ isc protheses should last for the lifetime of the patient, should be able to be contained in the normal intervertebral disc space, should have sufficient mechanical ~ , . .
W O 98/05274 PCT~US97/138S4 properties for normal body function, should be able to be fi~ed to the vertebrae adjacent to the disc, should be possible to - implant, should not cause any damage should the disc fail, and should be biocompatible.
There are at least 56 artificial disc designs which have been patented or identified as being investigated, McMillin C.R. and Steffee A.D., 20th Annual Meeting of the Society for Biomaterials (abstract)(1994), although not all these devices have actually been made or tested. They can be divided into two main cate~ories. Lee et al., Spine, Vol. 16, 253-255(1991). A first class includes devices for nucleus pulposus replacements which includes metal ball bearing, a silicone rubber nucleus, and a silicone fluid filled plastic tube. Devices for total or subtotal replacement of the disc have also been proposed such as a spring system, low-friction sliding surfaces, a fluid filled chamber, elastic disc prosthesis and elastic disc encased in a rigid column.
An example of total disc replacement is described by Urbaniak et al., Bio. J. Med. Mater. Res. Sym., Vol. 4, 165-186 (1973) who developed and tested, using chimpanzees, an intervertebral disc device made of a central silicone layer sandwiched between two layers of Dacron embedded in the silicone. The open-mesh Dacron was chosen to allow tissue ingrowth for fixation to the adjacent vertebrae. While spinal mobility was restored and the device tolerated by the host, due to inexact fit of the device, bone resorption and reactive bone formation were observable. Loose fibrous tissue also indicated possible movement of the device.
Hou et al., Chi~ese Medical Journal, Vol. 104(5), 381-386 (1991), developed a disc implant made of silicone ~ rubber which restored normal disc function. However, the presence of fibrous tissue surrounding the implant indicated possible movement of the device.
The SB Charite intervertebral disc endoprosthesis, White and Panjabi, Clinical biomechanics of the lumbar spine, Churchill Livingstone, London (1989), which has been tested clinically, is fabricated from a biconvex polyethylene core sandwiched between two concave-molded titanium end-plates.
However, the endoprosthesis shows insufficient mechanical performance and unlikely long-term bone fixation to the device.
Two types of disc prostheses were developed and evaluated by Lee et al., 35th Annual Meeting of the Ort~opaedic Research Society, Las Vegas, Nevada, February 6-9 (1989);
Dacron fiber-reinforced polyurethane elastomer (reinforcement located for the annulus section), and a prosthesis made from thermoplastic polymer which is increasingly rigid moving from the nucleus out to the end-plates. Yet another design is made of cobalt-chromium-molybdenum (Co-Cr-Mo) alloy by Hedman et al., Spine, Vol. 16, 256-60 (1991).
U.S. Patent No. 4,911,718 (Lee et al.), U.S. Patent No. 5,002,576 (Fuhrmann et al.), U.S. Patent No. 4,911,718 (Lee et al.) and U.S. Patent No. 5,458,642 (seer et al.) also teach permanent intervertebral disc endoprostheses for total disc replacement.
All of foregoing intervertebral disc prostheses, however, merely replace all or a part of the disc with synthetic materials which must remain in place ad infinitum.
These prostheses are generally permanent implants which require observation of long term biologic responses throughout the life of the prothesis. Furthermore, discs that are not comprised of biocompatible material may be rejected by the patient.
Procedures by which the tissues of the intervertebral disc are made to reform or replace the degenerated tissue of the intervertebral disc, would be highly desirable and a significant improvement over the current state of the art which presently use such permanent implants. Although efforts at tissue-engineering have been reported, no one has, until now, accomplished reformation of intervertebral disc tissue.
. . ~ ., W O 98t05274 PCT~US97113854 Repair of skin tissue has been achieved. For instance, skin deficiencies which arise in severely burnt patients or in decubitus wounds of diabetic patients have been so treated. Sabolinski, Biomaterials, Vol. 17, 311-320 (1996).
~ 5 Cells are seeded onto templates of either resorbable or non-resorbable material. Once tissue begins to form the templates are dressed onto the site in need of treatment. Tissue engineering of the skin, however, is significantly different from tissue engineering of the intervertebral disc because tissue compositions differ significantly. In addition, the mechanical requirements of engineered skin tissue are significantly different from those of intervertebral disc tissue.
Some intervertebral disc prostheses provide for regrowth of the intervertebral disc and concurrent resorption of the prothesis. For example, U.S. Patent Nos. 4,772,287 and 4,904,260 (Ray et al.~ teach prosthetic discs having an outer layer of strong, inert fibers intermingled with bioresorbable materials which attract tissue ingrowth. However, this prosthesis is purely a synthetic material at the time of implantation and does not include any cells or developing tissue. In addition, it provides only partial resorption and the problems associated with permanent implants remain.
U.S. Patent Nos. 5,108,43~ and 5,258,043 (Stone~
teach a porous matrix of biocompatible and bioresorbable fibers which may be interspersed with glycosaminoglycan molecules.
The matrix serves as a scaffold for regenerating disc tissue and replaces both the annulus fibrosus and nucleus pulposus.
However, replacement of this much tissue is a relatively invasive procedure which requires lengthy recovery time.
Furthermore, these matrices do not use any cells to stimulate tissue recovery nor is there any incipient tissue formatlon in this device at the time of implantation.
Various materials have been seeded with cells in order to facilitate cell function including proliferation and extracellular matrix synthesis. For instance, El-Ghannam, et al., ~ournal of Biomedical Materials Research, Vol. 23, 359-370 W O 98/05274 PCTrUS97/138S4 (1974), teaches in vitro synthesis of bone-like tissue using bioactive glass templates. Schepers, et al., J. Oral Rehab., Vol. 18, 439-452 (1991), analyzed the use of bioactive glass as fillers for bone lesions. Also, porous polymeric matrices have been used. The polymers include poly(lactic acid), poly~glycolic acid) and their co-polymers. However, these polymers have not been taught to be appropriate substrates for intervertebral disc cells which until now have not been used to seed implants of any sort.
Ideally, intervertebral disc treatment would guide and possibly stimulate the reformation of the tissue of affected intervertebral disc, especially nucleus pulposus and annulus fibrosus tissue. It could also biodegrade while allowing concurrent nucleus pulposus and annulus fibrosus tissue ingrowth, thereby providing for disc regeneration. Such an intervertebral disc material which is biodegradable while still satisfying the mechanical requirements of an intervertebral disc, has not been available until now.
OBJECTS OF I~HE lNV~llON
An object of the present invention is to provide a method of inducing and/or guiding intervertebral disc reformation using biodegradable support substrates.
In yet another object of the present invention is provided biodegradable substrates useful for intervertebral disc tissue reformation.
Still another object of the invention is to provide material useful for guiding and/or stimu~ating intervertebral disc tissue reformation.
Another object of the invention is to provide methods of culturing intervertebral disc cells.
, W O 98/05274 PCTrUS97113854 BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a perspective view of an exemplary hybrid material of the present invention.
SUMMARY OF THE 1NV~N 110N
In accordance with methods of the present invention there are provided methods for repairing damaged or degenerated intervertebral discs. These methods comprise evacuating tissue from the nucleus pulposus portion of a degenerated intervertebral disc space, preparing hybrid material by combining isolated intervertebral disc cells with a biodegradable substrate, and implanting the hybrid material in the evacuated nucleus pulposus space. In accordance with methods of the invention intervertebral disc cell growth is guided and/or stimulated and intervertebral disc tissue is reformed.
Methods of culturing intervertebral disc cells are also provided in some aspects of the invention whereby intervertebral disc tissue is digested with collagenase and incubated in medium supplemented with hyaluronidase.
In still other aspects of the invention biodegradable substrates are provided comprising polymer foam coated with bioactive materials, which substrates are useful for intervertebral disc tissue reformation.
In yet another aspect of the invention are provided hybrid materials for reforming degenerate intervertebral disc tissue. The hybrid materials can be made in the form of shaped bodies comprising biodegradable substrate and intervertebral disc cells.
DETAILED DESCRIPTION OF THE lNV~;NllON
The present invention is directed to methods of inducing intervertebral disc repair by reformation of intervertebral disc tissue. By implanting a hybrid material comprising intervertebral disc cells and a biodegradable WO 98/05274 rCT/US97/13854 support substrate into the intervertebral disc space, ingrowth of intervertebral disc cells is induced. Thus, the present invention provides methods of inducing self-regeneration of viable tissue and functional joints.
Methods of the present invention are useful to treat vertebrates suffering from degenerated intervertebral disc conditions, and in particular may be used to treat humans with such conditions.
A degenerated intervertebral disc has lost or damaged some or all of its intervertebral disc tissue, primarily including its nucleus pulposus tissue, due to any number of factors discussed herein, including age and stress due to rotational loading. Degenerated discs vary in severity from bulging discs to herniated or ruptured discs. Patients suffering from a degenerated disc experience a number of symptoms which include pain of the lower back, buttocks and legs and may also include sciatica and degenerative spondylolysis. In accordance with methods of the present invention reformation or regeneration of intervertebral disc tissue occurs in situ, replacing lost or damaged tissue and resulting in amelioration or elimination of the conditions associated with the degenerated disc.
In accordance with the present invention hybrid materials used to induce and/or guide reformation of intervertebral disc tissue comprise biodegradable substrates.
Biodegradable means that the substrate degrades into natural, biocompatible byproducts over time until the substrate is substantially eliminated from the implantation site and, ultimately, the body. Preferably in accordance with methods of the present invention, the rate of biodegradation of the substrate is less than or equal to the rate of intervertebral disc tissue formation such that the rate of tissue formation . . .
W O 98/05274 PCTrUS97/13854 is sufficient to replace the support material which has biodegraded.
In some aspects of the present invention the biodegradable substrate may be bioactive. Bioactive, as used herein, is meant to refer to substrates which enhance cell function as compared to cell function of the same cell type in the absence of the substrate. For instance, bioactive glass granules have been shown to enhance cell growth of typical bone cells. Schepers et al., U.S. Patent No. 5,204,106. In addition, dense bioactive glass discs have been found to enhance osteoprogenitor cell differentiation beyond even those levels of enhanced differentiation elicited by bone morphogenic protein. H. Baldick, et al., Transactions 5th World Biomaterials Conference, Toronto, II-114 (June, 1996).
The biodegradable substrate must also have sufficient mechanical strength to act as a load bearing spacer until intervertebral disc tissue is regenerated. In addition, the biodegradable substrate must be biocompatible such that it does not elicit an autoimmune or inflammatory response which might result in rejection of the implanted hybrid material.
Biodegradable support substrates useful in methods of the present invention include bioactive glass, polymer foam, and polymer foam coated with sol gel bioactive material.
In accordance with some methods of the present invention bioactive glass is employed as a substrate.
Bioactive glass is described in U.S. Patent No. 5,204,104, incorporated by reference herein in its entirety. The bioactive glass contains oxides of silicon, sodium, calcium and phosphorous in the following percentages by weight: about 40 to about 58~ SiO2, about 10 to about 30~ Na2O, about 10 to about 30~ CaO, and 0 to about 10~ P2Os. In preferred ~ embodiments of the invention the nominal composition of - bioactive glass by weight is 45~ SiO2, 24.5~ Na2O, 24.5~ CaO
and 6~ P2O5 and is known as 45S5 bioactive glass. Bioactive glass may be obtained from commercial sources such as Orthovita, Inc. (Malvern, PA).
W O 98/OS274 PCTrUS97113854 Granule size of the bioactive glass is selected based upon the degree of vascularity of the affected tissue and generally will be less than about 1000 ~m in diameter. In some embodiments of the present invention it is preferred that the bioactive glass granules be from about 200 ~m to about 300~m in diameter. In still other embodiments of the present invention granule size is from about 50~m to about 100~m.
In some embodiments of the present invention bioactive glass has pores. Percent density ~100~- percent porosity) of less than about 80~ may be used in some aspects of the invention. Percent density of about 10~ to about 68~
can be used for other aspects of the invention. In some aspects of the p-resent invention the pore size should be less than about 850 ~m in diameter while about 150~m to about 600 ~m pore diameter is preferred.
One method of preparing porous bioactive glass is by mixing bioactive glass granules of a desired size with sieved sacrificial agent camphor particles of a desired amount and size. The camphor sublimates during sintering leaving pores in the sintered glass. Thus, the average particle size and weight percent of the camphor particles is chosen to optimize the pore size and percent porosity, respectively, of the glass.
In some aspects of the invention particle size may be less than about 850 ~m in diameter while about 150~m to about 600~m is preferred. Thereafter the glass may be treated with any a~ueous buffer solution containing ions, the identity and concentration of which is found in interstitial fluid. Said treatments result in the formation of a calcium phosphate rich layer at the glass surface. Typical buffers include those prepared as described by Healy and Ducheyne, Biomaterials, Vol. 13, 553-561 (1992), the subject matter of which is incorporated herein by reference in its entirety.
W O 98105274 PCTrUS97113854 In still other aspects of the present invention the support substrate comprises polymer foam. Polymer foam useful - in these aspects of the invention are biocompatible and include polyglycolide (PGA), poly(D,L-lactide)(D,L-PLA), poly(L-lactide) (L-PLA), poly(D,L-lactide-co-glycolide),(D,L-PLGA),poly (L-lactide-co-glycolide) (L-PLGA), polycaprolatone(PCL),polydioxanone, polyesteramides, copolyoxalates, and polycarbonates. D,L-PLGA, which is preferred in some embodiments of the invention, may comprise 50% polylactide and 50% polyglycolide. About 75~ polylactide and about 25~ polyglycolide is still more preferred although it is anticipated that ratios may be varied to optimize particular features of the individual polymers. For instance, the mechanical strength of a polymer may be adjusted by varying the percentage of PLA and the percentage of PGA may be adjusted to optimize cell growth.
In some aspects of the invention polymer foam is coated with sol gel bioactive material. Sol gel materials include glasses and ceramics. Such bioactive compound are prepared by mixing a desired polymer foam with NaCl to create the desired porosity and pore size. Thereafter, the polymer, including the pores and interstices, is coated with sol gel material.
Sol gel glass is prepared by combining a metal alkoxide precursor with water and an acid catalyst to produce a gel. A typical process is described in U.S. Serial No.
08/477,585 (U.S. Patent No. ) which is incorporated by reference herein in its entirety. Once dried the gel consists mostly of metal oxide with a glass consistency. Sol gel bioactive material may be comprised of from about 60 to about 100~ silicon dioxide, up to about 40% calcium oxide and up to about 10% diphosphorous pentoxide. A final product of 70% SiO2, 25~ CaO and 5% P2Os is preferred in some methods of the present invention although the concentration of each may be adjusted to optimize critical features of the sol gel. Other sol gel materials may be prepared by methods known in the art. For instance, Qui, Q., et al., Cells and Materials, Vol. 3, 351-60 W O 98105274 PCT~US97/13854 (1993), incorporated by reference herein in its entirety, teaches methods of preparing calcium phosphate sol gel bioactive material.
To coat the polymer, the polymer foam is dipped into the sol during the sol gelation phase. The sol-filled foam is then placed in a syringe filter and the sol is pulled through the foam by creating a vacuum below using the syringe. Thus, the polymer is substantially coated with sol gel, with residual sol gel being evacuated from the polymer matrices. While it is preferred that most or all of the polymer surfaces, including the surfaces of the pores and interstices, be coated with sol gel bioactive glass, polymers which are only partially coated with sol gel bioactive glass may also be useful in some aspects of the present invention. It is desired in some embodiments of the invention that greater than about 50~ of the polymer surface be coated.
To prepare the hybrid material, intervertebral disc cells are combined with biodegradable substrate material.
Intervertebral disc cells may be isolated from tissue extracted from any accessible intervertebral disc of the spine. For instance, tissue may be extracted from the nucleus pulposus of lumbar discs, sacral discs or cervical discs. Preferably, intervertebral disc cells are primarily nucleus pulposus cells.
In some embodiments it is preferred that disc cells are at
FIELD OF THE lNv~NllON
The present invention concerns methods and materials useful for reforming degenerated discs of the spine of a vertebrate and in particular the spine of a human.
BACKGROUND OF THE lNv~~ lON
Back pain is one of the most frequently reported musculoskeletal problems in the United States. 80~ of the adults will miss work at least three times in their career due to back pain. The most common factor causing low back pain is the degeneration of the disc. At the ages between 35 to 37, approximately a third of the US population have suffered from a herniated disc.
The main functions of the spine are to allow motion, transmit load and protect the neural elements. The vertebrae of the spine articulate with each other to allow motion in the frontal, sagittal and transverse planes. As the weight of the upper body increases, the vertebral bodies which are designed to sustain mainly compressive loads, increase in size caudally.
The intervertebral disc is a major link between the adjacent vertebrae of the spine. The intervertebral disc, the surrounding ligaments and muscles provide stability to the splne .
The intervertebral discs make up about 20-33~ of the lumbar spine length. They are capable of sustaining weight and transferring the load from one vertebral body to the next, as well as maintaining a deformable space to accommodate normal spine movement. Each disc consists of a gelatinous nucleus pulposus surrounded by a laminated, fibrous annulus fibrosus, situated between the end plates of the vertebrae above and below.
The nucleus pulposus contains collagen fibrils and water-binding glycosaminoglycans. At birth, the nucleus pulposus contains 88~ water, however, this percentage decreases with age. This water loss decreases its ability to withstand stress. The annulus fibrosus consists of fibrocartilaginous tissue and fibrous protein. The collagen fibers are arranged in between 10 to 20 lamellae which form concentric rings around the nucleus pulposus. The collagen fibers within each lamella are parallel to each other and runs at an angle of approximately 60 degrees from vertical. The direction of the inclination alternates with each lamellae. This crisscross arrangement enables the annulus fibrosus to withstand torsional and bending loads. The end-plates are composed of hyaline cartilage, and are directly connected to the lamellae which form the inner one-third of the annulus.
When under compressive loads, the nucleus pulposus flattens and bulges out radially. The annulus fibrosus stretches, resisting the stress. The end-plates of the vertebral body also resist the ability of the nucleus pulposus to deform. Thus, pressure is applied against the annulus and end-plate, transmitting the compressive loads to the vertebral body. When tensile forces are applied, the disc is raised to a certain height straining the collagen fibers in the annulus.
At bending, one side of the disc is in tension while the other side is in compression. The annulus of the compressed side bulges out.
, . . .
When the disc is subjected to torsion, there are shear stresses which vary proportionally to the distance from the axis of rotation, in the horizontal and axial plane. The layer of fibers oriented in the angle of motion is in tension while the fibers in the preceding or succeeding layer are relaxed. Similarly in sliding, the fibers oriented in the sliding direction are in tension while the fibers in the other layers relax.
Repeated rotational loading initiates circumferential tears in the annulus fibrosus, which gradually form radial tears into the nucleus pulposus until the nucleus degrades within the disc. In addition to the water loss which occurs with age, more water is also lost due to nucleus rupture, thereby reducing its ability to resist compressive loads. As such, the annulus bulges. As the severity of the tear increases, much of the contents of the disc is lost leaving a thin space of fibrous tissue. This condition is called disc resorption.
Increasing disc collapse can cause facet subluxation and stenosis of the intervertebral foramen. Subsequently, the degenerative process involves the facet joints equally. As the annulus bulges out posteriorly into the spinal canal, the nerve root may be compressed causing sciatica. Pain is felt from the lower back to the buttocks and the leg. Following the rupture of the disc, excessive motions such as excessive extension or flexion can occur, resulting in spine segmental instability. The spine is thus more vulnerable to trauma.
Herniation can occur due to disc degeneration or excessive load factors especially compression. Pain may result due to nerve root compression caused by protrusions.
The unstable phase of the degeneration progress allowing excessive movement may result in degenerative ~ spondylolisthesis, which is a breakdown of posterior joints.
The nerve is trapped between the inferior articular facet of the vertebrae above and the body of that below. Thus, sliding of a vertebral body on another damages the posterior joints due W098t05274 PCT~S97/13854 to fatigue and apply traction on the nerve root causing pain.
Surgical treatments for herniated disc include laminectomy, spinal fusion and disc replacement with protheses.
At this time, 150,000 spinal fusion procedures are performed per year in the US alone, and the numbers are growing exponentially. However, the results of spinal fusions are very varied. Some of the effects include non-unions, slow rate of fusion even with autografts, and significant frequency of morbidity at the graft donor site. In addition, even if the fusion is successful, joint motion is totally eliminated.
Adverse effects of spinal fusions have also been reported on adjacent unfused segments such as disc degeneration, herniation, instability spondylolysis and facet joint arthritis. A long-term follow-up of lower lumbar fusions in patients from 21 to 52 years of age found that 4~ of patients with spinal fusions were currently still experiencing low-back pain and 57~ had back pain within the previous year. 53~ of the patients tracked were on medication, 5~ had late sequela secondary surgery, 15~ had a repeat lumbar surgery, 42~ had symptoms of spinal stenosis, and 45~ had instability proximal to their fusion. This clinical data shows that significant long-term limitations are associated with spinal fusion.
An alternative to spinal fusion is the use of an intervertebral disc prosthesis. Ideally, a successful disc prosthesis will simulate the function of a normal disc. The disc replacement must be capable of sustaining weight and transferring load from one vertebral body to the next. It should be robust enough not to ~e injured during movement and should maintain a deformable space between the vertebral body to accommodate movement.
~ isc protheses should last for the lifetime of the patient, should be able to be contained in the normal intervertebral disc space, should have sufficient mechanical ~ , . .
W O 98/05274 PCT~US97/138S4 properties for normal body function, should be able to be fi~ed to the vertebrae adjacent to the disc, should be possible to - implant, should not cause any damage should the disc fail, and should be biocompatible.
There are at least 56 artificial disc designs which have been patented or identified as being investigated, McMillin C.R. and Steffee A.D., 20th Annual Meeting of the Society for Biomaterials (abstract)(1994), although not all these devices have actually been made or tested. They can be divided into two main cate~ories. Lee et al., Spine, Vol. 16, 253-255(1991). A first class includes devices for nucleus pulposus replacements which includes metal ball bearing, a silicone rubber nucleus, and a silicone fluid filled plastic tube. Devices for total or subtotal replacement of the disc have also been proposed such as a spring system, low-friction sliding surfaces, a fluid filled chamber, elastic disc prosthesis and elastic disc encased in a rigid column.
An example of total disc replacement is described by Urbaniak et al., Bio. J. Med. Mater. Res. Sym., Vol. 4, 165-186 (1973) who developed and tested, using chimpanzees, an intervertebral disc device made of a central silicone layer sandwiched between two layers of Dacron embedded in the silicone. The open-mesh Dacron was chosen to allow tissue ingrowth for fixation to the adjacent vertebrae. While spinal mobility was restored and the device tolerated by the host, due to inexact fit of the device, bone resorption and reactive bone formation were observable. Loose fibrous tissue also indicated possible movement of the device.
Hou et al., Chi~ese Medical Journal, Vol. 104(5), 381-386 (1991), developed a disc implant made of silicone ~ rubber which restored normal disc function. However, the presence of fibrous tissue surrounding the implant indicated possible movement of the device.
The SB Charite intervertebral disc endoprosthesis, White and Panjabi, Clinical biomechanics of the lumbar spine, Churchill Livingstone, London (1989), which has been tested clinically, is fabricated from a biconvex polyethylene core sandwiched between two concave-molded titanium end-plates.
However, the endoprosthesis shows insufficient mechanical performance and unlikely long-term bone fixation to the device.
Two types of disc prostheses were developed and evaluated by Lee et al., 35th Annual Meeting of the Ort~opaedic Research Society, Las Vegas, Nevada, February 6-9 (1989);
Dacron fiber-reinforced polyurethane elastomer (reinforcement located for the annulus section), and a prosthesis made from thermoplastic polymer which is increasingly rigid moving from the nucleus out to the end-plates. Yet another design is made of cobalt-chromium-molybdenum (Co-Cr-Mo) alloy by Hedman et al., Spine, Vol. 16, 256-60 (1991).
U.S. Patent No. 4,911,718 (Lee et al.), U.S. Patent No. 5,002,576 (Fuhrmann et al.), U.S. Patent No. 4,911,718 (Lee et al.) and U.S. Patent No. 5,458,642 (seer et al.) also teach permanent intervertebral disc endoprostheses for total disc replacement.
All of foregoing intervertebral disc prostheses, however, merely replace all or a part of the disc with synthetic materials which must remain in place ad infinitum.
These prostheses are generally permanent implants which require observation of long term biologic responses throughout the life of the prothesis. Furthermore, discs that are not comprised of biocompatible material may be rejected by the patient.
Procedures by which the tissues of the intervertebral disc are made to reform or replace the degenerated tissue of the intervertebral disc, would be highly desirable and a significant improvement over the current state of the art which presently use such permanent implants. Although efforts at tissue-engineering have been reported, no one has, until now, accomplished reformation of intervertebral disc tissue.
. . ~ ., W O 98t05274 PCT~US97113854 Repair of skin tissue has been achieved. For instance, skin deficiencies which arise in severely burnt patients or in decubitus wounds of diabetic patients have been so treated. Sabolinski, Biomaterials, Vol. 17, 311-320 (1996).
~ 5 Cells are seeded onto templates of either resorbable or non-resorbable material. Once tissue begins to form the templates are dressed onto the site in need of treatment. Tissue engineering of the skin, however, is significantly different from tissue engineering of the intervertebral disc because tissue compositions differ significantly. In addition, the mechanical requirements of engineered skin tissue are significantly different from those of intervertebral disc tissue.
Some intervertebral disc prostheses provide for regrowth of the intervertebral disc and concurrent resorption of the prothesis. For example, U.S. Patent Nos. 4,772,287 and 4,904,260 (Ray et al.~ teach prosthetic discs having an outer layer of strong, inert fibers intermingled with bioresorbable materials which attract tissue ingrowth. However, this prosthesis is purely a synthetic material at the time of implantation and does not include any cells or developing tissue. In addition, it provides only partial resorption and the problems associated with permanent implants remain.
U.S. Patent Nos. 5,108,43~ and 5,258,043 (Stone~
teach a porous matrix of biocompatible and bioresorbable fibers which may be interspersed with glycosaminoglycan molecules.
The matrix serves as a scaffold for regenerating disc tissue and replaces both the annulus fibrosus and nucleus pulposus.
However, replacement of this much tissue is a relatively invasive procedure which requires lengthy recovery time.
Furthermore, these matrices do not use any cells to stimulate tissue recovery nor is there any incipient tissue formatlon in this device at the time of implantation.
Various materials have been seeded with cells in order to facilitate cell function including proliferation and extracellular matrix synthesis. For instance, El-Ghannam, et al., ~ournal of Biomedical Materials Research, Vol. 23, 359-370 W O 98/05274 PCTrUS97/138S4 (1974), teaches in vitro synthesis of bone-like tissue using bioactive glass templates. Schepers, et al., J. Oral Rehab., Vol. 18, 439-452 (1991), analyzed the use of bioactive glass as fillers for bone lesions. Also, porous polymeric matrices have been used. The polymers include poly(lactic acid), poly~glycolic acid) and their co-polymers. However, these polymers have not been taught to be appropriate substrates for intervertebral disc cells which until now have not been used to seed implants of any sort.
Ideally, intervertebral disc treatment would guide and possibly stimulate the reformation of the tissue of affected intervertebral disc, especially nucleus pulposus and annulus fibrosus tissue. It could also biodegrade while allowing concurrent nucleus pulposus and annulus fibrosus tissue ingrowth, thereby providing for disc regeneration. Such an intervertebral disc material which is biodegradable while still satisfying the mechanical requirements of an intervertebral disc, has not been available until now.
OBJECTS OF I~HE lNV~llON
An object of the present invention is to provide a method of inducing and/or guiding intervertebral disc reformation using biodegradable support substrates.
In yet another object of the present invention is provided biodegradable substrates useful for intervertebral disc tissue reformation.
Still another object of the invention is to provide material useful for guiding and/or stimu~ating intervertebral disc tissue reformation.
Another object of the invention is to provide methods of culturing intervertebral disc cells.
, W O 98/05274 PCTrUS97113854 BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a perspective view of an exemplary hybrid material of the present invention.
SUMMARY OF THE 1NV~N 110N
In accordance with methods of the present invention there are provided methods for repairing damaged or degenerated intervertebral discs. These methods comprise evacuating tissue from the nucleus pulposus portion of a degenerated intervertebral disc space, preparing hybrid material by combining isolated intervertebral disc cells with a biodegradable substrate, and implanting the hybrid material in the evacuated nucleus pulposus space. In accordance with methods of the invention intervertebral disc cell growth is guided and/or stimulated and intervertebral disc tissue is reformed.
Methods of culturing intervertebral disc cells are also provided in some aspects of the invention whereby intervertebral disc tissue is digested with collagenase and incubated in medium supplemented with hyaluronidase.
In still other aspects of the invention biodegradable substrates are provided comprising polymer foam coated with bioactive materials, which substrates are useful for intervertebral disc tissue reformation.
In yet another aspect of the invention are provided hybrid materials for reforming degenerate intervertebral disc tissue. The hybrid materials can be made in the form of shaped bodies comprising biodegradable substrate and intervertebral disc cells.
DETAILED DESCRIPTION OF THE lNV~;NllON
The present invention is directed to methods of inducing intervertebral disc repair by reformation of intervertebral disc tissue. By implanting a hybrid material comprising intervertebral disc cells and a biodegradable WO 98/05274 rCT/US97/13854 support substrate into the intervertebral disc space, ingrowth of intervertebral disc cells is induced. Thus, the present invention provides methods of inducing self-regeneration of viable tissue and functional joints.
Methods of the present invention are useful to treat vertebrates suffering from degenerated intervertebral disc conditions, and in particular may be used to treat humans with such conditions.
A degenerated intervertebral disc has lost or damaged some or all of its intervertebral disc tissue, primarily including its nucleus pulposus tissue, due to any number of factors discussed herein, including age and stress due to rotational loading. Degenerated discs vary in severity from bulging discs to herniated or ruptured discs. Patients suffering from a degenerated disc experience a number of symptoms which include pain of the lower back, buttocks and legs and may also include sciatica and degenerative spondylolysis. In accordance with methods of the present invention reformation or regeneration of intervertebral disc tissue occurs in situ, replacing lost or damaged tissue and resulting in amelioration or elimination of the conditions associated with the degenerated disc.
In accordance with the present invention hybrid materials used to induce and/or guide reformation of intervertebral disc tissue comprise biodegradable substrates.
Biodegradable means that the substrate degrades into natural, biocompatible byproducts over time until the substrate is substantially eliminated from the implantation site and, ultimately, the body. Preferably in accordance with methods of the present invention, the rate of biodegradation of the substrate is less than or equal to the rate of intervertebral disc tissue formation such that the rate of tissue formation . . .
W O 98/05274 PCTrUS97/13854 is sufficient to replace the support material which has biodegraded.
In some aspects of the present invention the biodegradable substrate may be bioactive. Bioactive, as used herein, is meant to refer to substrates which enhance cell function as compared to cell function of the same cell type in the absence of the substrate. For instance, bioactive glass granules have been shown to enhance cell growth of typical bone cells. Schepers et al., U.S. Patent No. 5,204,106. In addition, dense bioactive glass discs have been found to enhance osteoprogenitor cell differentiation beyond even those levels of enhanced differentiation elicited by bone morphogenic protein. H. Baldick, et al., Transactions 5th World Biomaterials Conference, Toronto, II-114 (June, 1996).
The biodegradable substrate must also have sufficient mechanical strength to act as a load bearing spacer until intervertebral disc tissue is regenerated. In addition, the biodegradable substrate must be biocompatible such that it does not elicit an autoimmune or inflammatory response which might result in rejection of the implanted hybrid material.
Biodegradable support substrates useful in methods of the present invention include bioactive glass, polymer foam, and polymer foam coated with sol gel bioactive material.
In accordance with some methods of the present invention bioactive glass is employed as a substrate.
Bioactive glass is described in U.S. Patent No. 5,204,104, incorporated by reference herein in its entirety. The bioactive glass contains oxides of silicon, sodium, calcium and phosphorous in the following percentages by weight: about 40 to about 58~ SiO2, about 10 to about 30~ Na2O, about 10 to about 30~ CaO, and 0 to about 10~ P2Os. In preferred ~ embodiments of the invention the nominal composition of - bioactive glass by weight is 45~ SiO2, 24.5~ Na2O, 24.5~ CaO
and 6~ P2O5 and is known as 45S5 bioactive glass. Bioactive glass may be obtained from commercial sources such as Orthovita, Inc. (Malvern, PA).
W O 98/OS274 PCTrUS97113854 Granule size of the bioactive glass is selected based upon the degree of vascularity of the affected tissue and generally will be less than about 1000 ~m in diameter. In some embodiments of the present invention it is preferred that the bioactive glass granules be from about 200 ~m to about 300~m in diameter. In still other embodiments of the present invention granule size is from about 50~m to about 100~m.
In some embodiments of the present invention bioactive glass has pores. Percent density ~100~- percent porosity) of less than about 80~ may be used in some aspects of the invention. Percent density of about 10~ to about 68~
can be used for other aspects of the invention. In some aspects of the p-resent invention the pore size should be less than about 850 ~m in diameter while about 150~m to about 600 ~m pore diameter is preferred.
One method of preparing porous bioactive glass is by mixing bioactive glass granules of a desired size with sieved sacrificial agent camphor particles of a desired amount and size. The camphor sublimates during sintering leaving pores in the sintered glass. Thus, the average particle size and weight percent of the camphor particles is chosen to optimize the pore size and percent porosity, respectively, of the glass.
In some aspects of the invention particle size may be less than about 850 ~m in diameter while about 150~m to about 600~m is preferred. Thereafter the glass may be treated with any a~ueous buffer solution containing ions, the identity and concentration of which is found in interstitial fluid. Said treatments result in the formation of a calcium phosphate rich layer at the glass surface. Typical buffers include those prepared as described by Healy and Ducheyne, Biomaterials, Vol. 13, 553-561 (1992), the subject matter of which is incorporated herein by reference in its entirety.
W O 98105274 PCTrUS97113854 In still other aspects of the present invention the support substrate comprises polymer foam. Polymer foam useful - in these aspects of the invention are biocompatible and include polyglycolide (PGA), poly(D,L-lactide)(D,L-PLA), poly(L-lactide) (L-PLA), poly(D,L-lactide-co-glycolide),(D,L-PLGA),poly (L-lactide-co-glycolide) (L-PLGA), polycaprolatone(PCL),polydioxanone, polyesteramides, copolyoxalates, and polycarbonates. D,L-PLGA, which is preferred in some embodiments of the invention, may comprise 50% polylactide and 50% polyglycolide. About 75~ polylactide and about 25~ polyglycolide is still more preferred although it is anticipated that ratios may be varied to optimize particular features of the individual polymers. For instance, the mechanical strength of a polymer may be adjusted by varying the percentage of PLA and the percentage of PGA may be adjusted to optimize cell growth.
In some aspects of the invention polymer foam is coated with sol gel bioactive material. Sol gel materials include glasses and ceramics. Such bioactive compound are prepared by mixing a desired polymer foam with NaCl to create the desired porosity and pore size. Thereafter, the polymer, including the pores and interstices, is coated with sol gel material.
Sol gel glass is prepared by combining a metal alkoxide precursor with water and an acid catalyst to produce a gel. A typical process is described in U.S. Serial No.
08/477,585 (U.S. Patent No. ) which is incorporated by reference herein in its entirety. Once dried the gel consists mostly of metal oxide with a glass consistency. Sol gel bioactive material may be comprised of from about 60 to about 100~ silicon dioxide, up to about 40% calcium oxide and up to about 10% diphosphorous pentoxide. A final product of 70% SiO2, 25~ CaO and 5% P2Os is preferred in some methods of the present invention although the concentration of each may be adjusted to optimize critical features of the sol gel. Other sol gel materials may be prepared by methods known in the art. For instance, Qui, Q., et al., Cells and Materials, Vol. 3, 351-60 W O 98105274 PCT~US97/13854 (1993), incorporated by reference herein in its entirety, teaches methods of preparing calcium phosphate sol gel bioactive material.
To coat the polymer, the polymer foam is dipped into the sol during the sol gelation phase. The sol-filled foam is then placed in a syringe filter and the sol is pulled through the foam by creating a vacuum below using the syringe. Thus, the polymer is substantially coated with sol gel, with residual sol gel being evacuated from the polymer matrices. While it is preferred that most or all of the polymer surfaces, including the surfaces of the pores and interstices, be coated with sol gel bioactive glass, polymers which are only partially coated with sol gel bioactive glass may also be useful in some aspects of the present invention. It is desired in some embodiments of the invention that greater than about 50~ of the polymer surface be coated.
To prepare the hybrid material, intervertebral disc cells are combined with biodegradable substrate material.
Intervertebral disc cells may be isolated from tissue extracted from any accessible intervertebral disc of the spine. For instance, tissue may be extracted from the nucleus pulposus of lumbar discs, sacral discs or cervical discs. Preferably, intervertebral disc cells are primarily nucleus pulposus cells.
In some embodiments it is preferred that disc cells are at
2~ least 50~ nucleus pulposus cells while 90~ nucleus pulposus cells is still more preferred. Cells may be obtained from the patient being treated, or alternatively cells may be extracted from donor tissue.
The present invention provides advantages over prior art methods in that the entire degenerated disc need not be removed to treat a degenerated disc. Rather, only the nucleus pulposus tissue need be evacuated from the degenerated intervertebral disc. Degenerated nucleus pulposus refers to W O 98/05274 PCT~US97113854 a region of the intervertebral disc where the tissue has severely reduced mechanical properties or which has lost some or most of the nucleus pulposus tissue. The present invention thus provides a less invasive procedure than that of the prior ~ 5 art. In addition, the methods and hybrid materials of the present invention prompt biological repair of normal tissue in the disc which will result in better long term results than that obtained with synthetic prostheses.
Evacuation of the degenerated intervertebral disc tissue, and primarily the nucleus pulposus ~issue, is performed using known surgical tools with procedures developed to meet the needs of the present invention. Generally an incision or bore is made at the lateral edge in the annulus fibrosus and the intervertebral disc tissue is extracted from the nucleus pulposus via, for example, the guillotine cutting approach.
The tissue may be extracted using a scalpel, bore, or curette.
Alternatively, tissue may be aspirated. Ideally, the annulus fibrosus, or significant portions thereof, are left intact. It is preferred for instance, that at least 50~ of the annulus fibrosus remain intact. It is still more preferred that at least 85~ of the annulus fibrosis remain intact. Arthroscopic techniques are most preferred in accordance with methods of the present invention.
Similar surgical techniques are utilized to extract intervertebral disc tissue from other, non-degenerate intervertebral discs of the spine of the patient or donor. For instance, similar techniques may be used to obtain intervertebral tissue from sacral discs. Minor modifications necessary to tailor the procedure to a particular region of the spine would be appreciated by those skilled in the art.
Where there is lag time between tissue evacuation and implantation of the hybrid material, the evacuated space may be temporarily filled with gel foam or other load bearing spacers known in the art.
Intervertebral disc cells are isolated from extracted tissue. Generally, tissue is fragmented and treated with W 098105274 PCTrUS97/138~t4 enzymes such as collagenase to disaggregate the cells into individual cells. Preferably isolated cells are primarily nucleus pulposus cells with 50~ nucleus pulposus cells being preferred and 90% nucleus pulposus cells being more preferred.
The cells are isolated using centrifugation. Cells may then be combined with a biodegradable substrate and implanted into the evacuated nucleus pulposus. Alternatively, isolated intervertebral disc cells may be cultured alone or seeded onto a biodegradable substrate and cultured together with the biodegradable substrate for later implantation.
In some aspects of the present invention the hybrid material may also include factors to enhance cell growth. For instance, TGF-~ and EGF may be added to the hybrid material to enhance cell growth. Cells may be incubated alone or seeded on a substrate in a tissue culture medium such as Dulbecco's Modified Eagle Medium (DMEM) (pH 7.0), which may be supplemented with serum such as heat-inactivated fetal bovine serum. Antifungal and antibacterial agents may also be added.
In preferred methods of the present invention cells are incubated with about 0.5~ to about 1.5~ hyaluronidase.
In some aspects of the present invention the end plate may be partially decorticated to enhance vascularization.
Thereafter, cells may be implanted or alternatively, after cell attachment, hyaluronidase is removed and incubation is resumed with a medium supplemented with 0.001~ ascorbic acid in the absence of hyaluronidase. Medium supplemented with 0.0025 ascorbic acid is used to replenish the cell solutions.
Hybrids of intervertebral disc cells and biodegradable substrate may then be implanted into the evacuated intervertebral disc space using surgical procedure such as described above.
Hybrid materials are provided by the present invention. Such hybrids can then be shaped for insertion into . . .. . .. .... .. . ... .. ....
W098/0~274 PCT~S97/13854 the intervertebral disc space of a patient. Exemplary Figure l shows a shaped hybrid material comprising biodegradable substrate and intervertebral cells. Intervertebral cells are located on the outer surface lO and on the surfaces of the pores and interstices 12 of the shaped substrate. It should be noted that Fi~ure l depicts one possible embodiment and should not be construed as limiting the invention in any way.
The substrate should generally have a rectangular shape. A cylindrical pad shape is also envisioned.
The following examples are illustrative but are not meant to be limiting of the present invention.
EXAMPLES
Example l Evacuation of Nucleus Pulposus Mature New Zealand rabbits weighing 4 - 5 kg are used. For each rabbit, L4-L5 or, when possible L4-L5 and ~5-L6 disc spaces are accessed as those are the biggest sections.
The anesthetics Ketamine, HCl 30 mg/kg, and Xylazine 6 mg/kg, are administered intramuscularly. Using a paraspinal posterolateral splitting approach, the large cephalad-facing transverse process of the lumbar spine is identified and removed with a rongeur. The intervertebral disc can then be seen. An incision is made in the annulus fibrosus. Using a high-power surgical microscope, the nucleus pulposus tissue is scraped out carefully with a curette. The space is then packed with gel foam. The rabbit is closed provisionally.
Example 2 Iso~ation of Intervertebral Disc Cells Intervertebral disc tissue is obtained as described in Example l or from an amputated tail section. Under aseptic condition, the intervertebral disc tissue is diced with a scalpel and placed in a T25 tissue culture flask with Dulbecco~s Modified Eagle Medium (DMEM) adjusted to pH 7.0, WOg8/05274 PCT~S97113854 supplemented with l0~ heat inactivated fetal bovine serum and l~penicillin/streptomycin ~TCM). The tissue is then treated with 0.25~ collagenase for two hours at 37~C. An equal amount of TCM to collagenase is added to stop treatment. The mixture is centrifuged at l000r/min for l0 minutes and supernatant is discarded. TCM is added and the mixture is filtered to remove debris. The mixture is again centrifuged and supernatant discarded. Cells are resuspended in TCM supplemented with l~
hyaluronidase (40Ou/ml).
Example 3 Culture of Intervertebral Disc Cells Cells are cultured in TCM supplemented with l~
hyaluronidase (400units/ml) at 37~C in 5% C02/95~ air. Once cells attach medium is changed to TCM supplemented with 0.00l~
ascorbic acid in the absence of hyaluronidase. Cells are resuspended in fresh medium supplemented with 0.0025~ ascorbic acid every 3 days.
Example 4 Preparation of Bioactive Glass Bioactive glass granules (45S5) having diameters of 40~m to 71 ~m, and 200-300~m, can be obtained from Orthovita, Inc. (Malvern, PA). Prior to implantation or addition to cell culture, the specimens are sterilized in ethylene oxide.
Example 5 Preparation of Sintered Porous Bioactive Glass Bioactive glass granules having diameters of 40~m to 71 ~m can be obtained from Orthovita, Inc. (Malvern, PA). The glass granules are mixed with 20.2 weight ~ sieved sacrificial agent camphor CloH16O with grain size of 300~m to 500~m. The , .. ... . . .
. . .
W O g8/05274 PCT~US97/138~4 mixture is mechanically mixed overnight, and cold pressed at 350 MPa. The disc obtained is heat treated at 575~C for 45 ~minutes. The heating rate is 10~C/min. It is then left to cool at room temperature. The disc is immersed in acetone for 30 -5 minutes and dried at 37~C. The disc is cut to the desired dimensions using a diamond-wheel saw. The disc is washed in acetone for 15 minutes. The specimen is then conditioned in tris buffer with electrolytes added (TE) (El-Ghi~nn~m, et al., Journal of Blomedical Materials Research, Vol. 29, 359-370 (1974)), for 2 days to obtain the desired formation of calcium phosphate-rich layer at the glass surface. The specimen is rinsed with methanol and dried at 37~C. The specimen is analyzed using scanning electron microscopy (SEM), Fourier Transform Infrared (FTIR) spectroscopy and X-ray diffraction (XRD). Prior to implantation or introduction to cell culture, the specimen is sterilized in ethylene oxide.
Example 6 Preparation of Polymer Foam 3g of NaCl with particle sizes 300~m to 500~m, and 2g of D,L-PLGA 75/25 (75~ polylactide/25~ polyglycolide) polymer foam were mixed. The dispersion is vortexed and cast in a 5cm petri dish. The solvent is a~lowed to evaporate from the covered petri dish for 48 hrs. To remove residual amounts of chloroform, the petri dish is vacuum-dried at 13 Pa for 24 hrs. The material is then immersed in 250ml distilled deionized water at 37~C for 96 hrs. The water is changed every 12 hrs to leach out the salt. The salt-free membrane is air-dried for 24 hrs, followed by vacuum-drying at 13 Pa for 48 hrs. The material is then cut to the desired geometry with a razor blade. The membrane is stored in a desiccator under vacuum. The specimens are analyzed using SEM. The specimen will have 60~ pore density with pore sizes 300 to 500~m. Prior to implantation or introduction into cell culture, the specimens are sterilized in ethylene oxide.
W O g8/05274 PCT~US97/138~4 Example 7 Preparation of Polymer Foam coated with Sol Gel Bioactive Glass Tetramethylorthosilane(TMOS),calcium methoxyethoxide and triethyl phosphate are mixed for 5 minutes in an argon atmosphere using a magnetic stirrer. Respective amounts of each are chosen such that the resulting product is 70~ SiO2-25~CaO-5~P202 (upon drying). They are mixed using a magnetic stirrer for 5 min. The PLGA polymer foam prepared according to Example 5 is dipped into the sol approximately halfway to gelation. The foam is dipped 2 to 3 times to make sure that the sol completely fills the polymer foam. The sol-filled foam is then placed in a syringe filter with appropriate filter pore size which only allows the sol to flow through. This syringe filter is attached to a syringe. The sol is pulled through the foam by creating a vacuum below using the syringe. EDAX and SEM are used to analyze pore size, porosity and the thickness/uniformity of the sol gel bioactive glass coating.
Prior to implantation or introduction to cell culture, the specimens are sterilized in ethylene oxide.
Example 8 Cell Phenotype Cell phenotype of cells cultured in accordance with the method of Example 3 is examined. Immunofluorescent staining of cells shows positive staining for proteoglycan and collagen type II, markers of intervertebral disc cell phenotype. Substantially negative staining for collagen I, a annulus fibrosus marker, was also observed initially.
Subsequently, positive staining for collagen I was also observed.
WO ~/05274 PCT~S97tl3854 Example 9 Cell Reversion Intervertebral disc cells cultured as described in Example 3 are tested for reversion. Cells are placed in Eppendorf tube with TCM and spun down to form a pellet. Cell histology is examined after 4, 8 and 12 days by washing the pellet and fixing it with 70% ethanol. The cells are dehydrated, embedded and cut. The sample is stained with hematoxylin-eosin and toluidine blue.
The histology of cultured cells is compared to the histology of nucleus pulposus tissue prepared immediately upon retrieval. Histology of the cells evidences a reversion to the original morphology of the cells.
Example lO
~mplantation of Biodegradable Substrate Cells are prepared in accordance with Examples 2 and
The present invention provides advantages over prior art methods in that the entire degenerated disc need not be removed to treat a degenerated disc. Rather, only the nucleus pulposus tissue need be evacuated from the degenerated intervertebral disc. Degenerated nucleus pulposus refers to W O 98/05274 PCT~US97113854 a region of the intervertebral disc where the tissue has severely reduced mechanical properties or which has lost some or most of the nucleus pulposus tissue. The present invention thus provides a less invasive procedure than that of the prior ~ 5 art. In addition, the methods and hybrid materials of the present invention prompt biological repair of normal tissue in the disc which will result in better long term results than that obtained with synthetic prostheses.
Evacuation of the degenerated intervertebral disc tissue, and primarily the nucleus pulposus ~issue, is performed using known surgical tools with procedures developed to meet the needs of the present invention. Generally an incision or bore is made at the lateral edge in the annulus fibrosus and the intervertebral disc tissue is extracted from the nucleus pulposus via, for example, the guillotine cutting approach.
The tissue may be extracted using a scalpel, bore, or curette.
Alternatively, tissue may be aspirated. Ideally, the annulus fibrosus, or significant portions thereof, are left intact. It is preferred for instance, that at least 50~ of the annulus fibrosus remain intact. It is still more preferred that at least 85~ of the annulus fibrosis remain intact. Arthroscopic techniques are most preferred in accordance with methods of the present invention.
Similar surgical techniques are utilized to extract intervertebral disc tissue from other, non-degenerate intervertebral discs of the spine of the patient or donor. For instance, similar techniques may be used to obtain intervertebral tissue from sacral discs. Minor modifications necessary to tailor the procedure to a particular region of the spine would be appreciated by those skilled in the art.
Where there is lag time between tissue evacuation and implantation of the hybrid material, the evacuated space may be temporarily filled with gel foam or other load bearing spacers known in the art.
Intervertebral disc cells are isolated from extracted tissue. Generally, tissue is fragmented and treated with W 098105274 PCTrUS97/138~t4 enzymes such as collagenase to disaggregate the cells into individual cells. Preferably isolated cells are primarily nucleus pulposus cells with 50~ nucleus pulposus cells being preferred and 90% nucleus pulposus cells being more preferred.
The cells are isolated using centrifugation. Cells may then be combined with a biodegradable substrate and implanted into the evacuated nucleus pulposus. Alternatively, isolated intervertebral disc cells may be cultured alone or seeded onto a biodegradable substrate and cultured together with the biodegradable substrate for later implantation.
In some aspects of the present invention the hybrid material may also include factors to enhance cell growth. For instance, TGF-~ and EGF may be added to the hybrid material to enhance cell growth. Cells may be incubated alone or seeded on a substrate in a tissue culture medium such as Dulbecco's Modified Eagle Medium (DMEM) (pH 7.0), which may be supplemented with serum such as heat-inactivated fetal bovine serum. Antifungal and antibacterial agents may also be added.
In preferred methods of the present invention cells are incubated with about 0.5~ to about 1.5~ hyaluronidase.
In some aspects of the present invention the end plate may be partially decorticated to enhance vascularization.
Thereafter, cells may be implanted or alternatively, after cell attachment, hyaluronidase is removed and incubation is resumed with a medium supplemented with 0.001~ ascorbic acid in the absence of hyaluronidase. Medium supplemented with 0.0025 ascorbic acid is used to replenish the cell solutions.
Hybrids of intervertebral disc cells and biodegradable substrate may then be implanted into the evacuated intervertebral disc space using surgical procedure such as described above.
Hybrid materials are provided by the present invention. Such hybrids can then be shaped for insertion into . . .. . .. .... .. . ... .. ....
W098/0~274 PCT~S97/13854 the intervertebral disc space of a patient. Exemplary Figure l shows a shaped hybrid material comprising biodegradable substrate and intervertebral cells. Intervertebral cells are located on the outer surface lO and on the surfaces of the pores and interstices 12 of the shaped substrate. It should be noted that Fi~ure l depicts one possible embodiment and should not be construed as limiting the invention in any way.
The substrate should generally have a rectangular shape. A cylindrical pad shape is also envisioned.
The following examples are illustrative but are not meant to be limiting of the present invention.
EXAMPLES
Example l Evacuation of Nucleus Pulposus Mature New Zealand rabbits weighing 4 - 5 kg are used. For each rabbit, L4-L5 or, when possible L4-L5 and ~5-L6 disc spaces are accessed as those are the biggest sections.
The anesthetics Ketamine, HCl 30 mg/kg, and Xylazine 6 mg/kg, are administered intramuscularly. Using a paraspinal posterolateral splitting approach, the large cephalad-facing transverse process of the lumbar spine is identified and removed with a rongeur. The intervertebral disc can then be seen. An incision is made in the annulus fibrosus. Using a high-power surgical microscope, the nucleus pulposus tissue is scraped out carefully with a curette. The space is then packed with gel foam. The rabbit is closed provisionally.
Example 2 Iso~ation of Intervertebral Disc Cells Intervertebral disc tissue is obtained as described in Example l or from an amputated tail section. Under aseptic condition, the intervertebral disc tissue is diced with a scalpel and placed in a T25 tissue culture flask with Dulbecco~s Modified Eagle Medium (DMEM) adjusted to pH 7.0, WOg8/05274 PCT~S97113854 supplemented with l0~ heat inactivated fetal bovine serum and l~penicillin/streptomycin ~TCM). The tissue is then treated with 0.25~ collagenase for two hours at 37~C. An equal amount of TCM to collagenase is added to stop treatment. The mixture is centrifuged at l000r/min for l0 minutes and supernatant is discarded. TCM is added and the mixture is filtered to remove debris. The mixture is again centrifuged and supernatant discarded. Cells are resuspended in TCM supplemented with l~
hyaluronidase (40Ou/ml).
Example 3 Culture of Intervertebral Disc Cells Cells are cultured in TCM supplemented with l~
hyaluronidase (400units/ml) at 37~C in 5% C02/95~ air. Once cells attach medium is changed to TCM supplemented with 0.00l~
ascorbic acid in the absence of hyaluronidase. Cells are resuspended in fresh medium supplemented with 0.0025~ ascorbic acid every 3 days.
Example 4 Preparation of Bioactive Glass Bioactive glass granules (45S5) having diameters of 40~m to 71 ~m, and 200-300~m, can be obtained from Orthovita, Inc. (Malvern, PA). Prior to implantation or addition to cell culture, the specimens are sterilized in ethylene oxide.
Example 5 Preparation of Sintered Porous Bioactive Glass Bioactive glass granules having diameters of 40~m to 71 ~m can be obtained from Orthovita, Inc. (Malvern, PA). The glass granules are mixed with 20.2 weight ~ sieved sacrificial agent camphor CloH16O with grain size of 300~m to 500~m. The , .. ... . . .
. . .
W O g8/05274 PCT~US97/138~4 mixture is mechanically mixed overnight, and cold pressed at 350 MPa. The disc obtained is heat treated at 575~C for 45 ~minutes. The heating rate is 10~C/min. It is then left to cool at room temperature. The disc is immersed in acetone for 30 -5 minutes and dried at 37~C. The disc is cut to the desired dimensions using a diamond-wheel saw. The disc is washed in acetone for 15 minutes. The specimen is then conditioned in tris buffer with electrolytes added (TE) (El-Ghi~nn~m, et al., Journal of Blomedical Materials Research, Vol. 29, 359-370 (1974)), for 2 days to obtain the desired formation of calcium phosphate-rich layer at the glass surface. The specimen is rinsed with methanol and dried at 37~C. The specimen is analyzed using scanning electron microscopy (SEM), Fourier Transform Infrared (FTIR) spectroscopy and X-ray diffraction (XRD). Prior to implantation or introduction to cell culture, the specimen is sterilized in ethylene oxide.
Example 6 Preparation of Polymer Foam 3g of NaCl with particle sizes 300~m to 500~m, and 2g of D,L-PLGA 75/25 (75~ polylactide/25~ polyglycolide) polymer foam were mixed. The dispersion is vortexed and cast in a 5cm petri dish. The solvent is a~lowed to evaporate from the covered petri dish for 48 hrs. To remove residual amounts of chloroform, the petri dish is vacuum-dried at 13 Pa for 24 hrs. The material is then immersed in 250ml distilled deionized water at 37~C for 96 hrs. The water is changed every 12 hrs to leach out the salt. The salt-free membrane is air-dried for 24 hrs, followed by vacuum-drying at 13 Pa for 48 hrs. The material is then cut to the desired geometry with a razor blade. The membrane is stored in a desiccator under vacuum. The specimens are analyzed using SEM. The specimen will have 60~ pore density with pore sizes 300 to 500~m. Prior to implantation or introduction into cell culture, the specimens are sterilized in ethylene oxide.
W O g8/05274 PCT~US97/138~4 Example 7 Preparation of Polymer Foam coated with Sol Gel Bioactive Glass Tetramethylorthosilane(TMOS),calcium methoxyethoxide and triethyl phosphate are mixed for 5 minutes in an argon atmosphere using a magnetic stirrer. Respective amounts of each are chosen such that the resulting product is 70~ SiO2-25~CaO-5~P202 (upon drying). They are mixed using a magnetic stirrer for 5 min. The PLGA polymer foam prepared according to Example 5 is dipped into the sol approximately halfway to gelation. The foam is dipped 2 to 3 times to make sure that the sol completely fills the polymer foam. The sol-filled foam is then placed in a syringe filter with appropriate filter pore size which only allows the sol to flow through. This syringe filter is attached to a syringe. The sol is pulled through the foam by creating a vacuum below using the syringe. EDAX and SEM are used to analyze pore size, porosity and the thickness/uniformity of the sol gel bioactive glass coating.
Prior to implantation or introduction to cell culture, the specimens are sterilized in ethylene oxide.
Example 8 Cell Phenotype Cell phenotype of cells cultured in accordance with the method of Example 3 is examined. Immunofluorescent staining of cells shows positive staining for proteoglycan and collagen type II, markers of intervertebral disc cell phenotype. Substantially negative staining for collagen I, a annulus fibrosus marker, was also observed initially.
Subsequently, positive staining for collagen I was also observed.
WO ~/05274 PCT~S97tl3854 Example 9 Cell Reversion Intervertebral disc cells cultured as described in Example 3 are tested for reversion. Cells are placed in Eppendorf tube with TCM and spun down to form a pellet. Cell histology is examined after 4, 8 and 12 days by washing the pellet and fixing it with 70% ethanol. The cells are dehydrated, embedded and cut. The sample is stained with hematoxylin-eosin and toluidine blue.
The histology of cultured cells is compared to the histology of nucleus pulposus tissue prepared immediately upon retrieval. Histology of the cells evidences a reversion to the original morphology of the cells.
Example lO
~mplantation of Biodegradable Substrate Cells are prepared in accordance with Examples 2 and
3. Cells are counted. Biodegradable substrates prepared as described in Examples 4-7 each placed in a tissue culture dish and immersed in TCM for 1 hour. The cells are seeded onto each of the sterile biodegradable substrates prepared as described in Examples 4-7 in TCM with hyaluronidase and left to attach for at least one hour before flooding the dish with TCM. Cells are incubated overnight. Attachment is detected using SEM.
The rabbit treated as described in Example 1 is reopened per surgical technique described in Example 1, and the intervertebral disc space accessed. The gel foam is retrieved and the cell-biodegradable substrate hybrid material inserted in place. The wound is closed.
Example 11 Effect on Neurological Function Regular post-operative neurological functions are evaluated to examine the subject for any spinal injury such as lameness. The effect of the hybrid material on the behavior of W O 98/05274 PCT~US97/13854 the disc can be observed and generally compared by taking radiographs of the spine immediately pre-operation, post-operation and at 1 month time periods until the animal is sacrificed.
Example 12 Histological analysis Histological analysis is performed to determine cell ingrowth, cell types, tissue morphology, and absence of inflammation. To this end, the retrieved disc is fixed in 70 ethanol and dehydrated. After embedding in methyl methacrylate, sections are cut with a diamond saw, ground, polished with silicon carbide paper and diamond paste, and stained.
Histology is done on normal discs and discs retrieved at the various time periods. Analysis will show ingrowth of cells with concurrent degradation of implanted hybrid material with little to no inflammation.
The rabbit treated as described in Example 1 is reopened per surgical technique described in Example 1, and the intervertebral disc space accessed. The gel foam is retrieved and the cell-biodegradable substrate hybrid material inserted in place. The wound is closed.
Example 11 Effect on Neurological Function Regular post-operative neurological functions are evaluated to examine the subject for any spinal injury such as lameness. The effect of the hybrid material on the behavior of W O 98/05274 PCT~US97/13854 the disc can be observed and generally compared by taking radiographs of the spine immediately pre-operation, post-operation and at 1 month time periods until the animal is sacrificed.
Example 12 Histological analysis Histological analysis is performed to determine cell ingrowth, cell types, tissue morphology, and absence of inflammation. To this end, the retrieved disc is fixed in 70 ethanol and dehydrated. After embedding in methyl methacrylate, sections are cut with a diamond saw, ground, polished with silicon carbide paper and diamond paste, and stained.
Histology is done on normal discs and discs retrieved at the various time periods. Analysis will show ingrowth of cells with concurrent degradation of implanted hybrid material with little to no inflammation.
Claims (44)
1. A method of reforming intervertebral disc tissue of a degenerated nucleus pulposus of a patient comprising the steps of evacuating intervertebral disc tissue from a degenerated nucleus pulposus;
preparing a hybrid material by combining intervertebral disc cells with a biodegradable substrate; and implanting the hybrid material in the evacuated nucleus pulposus space.
preparing a hybrid material by combining intervertebral disc cells with a biodegradable substrate; and implanting the hybrid material in the evacuated nucleus pulposus space.
2. The method of claim 1 wherein the biodegradable substrate is bioactive.
3. The method of claim 1 wherein the biodegradable substrate is bioactive glass, polymer foam, or polymer foam coated with sol gel bioactive material.
4. The method of claim 3 wherein the polymer foam is the copolymer D,L poly(lactide-co-glycolide).
5. The method of claim 4 wherein the copolymer comprises 75% polylactide and 25% glycolide.
6. The method of claim 1 further comprising isolating cells from an intervertebral disc.
7. The method of claim 6 wherein cells are isolated from the nucleus pulposus of an intervertebral disc.
8. The method of claim 6 further comprising culturing intervertebral cells on a biodegradable substrate prior to implantation.
9. The method of claim 6 further comprising culturing intervertebral cells prior to combining cells with a biodegradable substrate.
10. The method of claim 9 wherein intervertebral cells are combined with a biodegradable substrate to form a hybrid material immediately prior to implanting the hybrid in the evacuated nucleus pulposus space.
11. The method of claim 1 wherein the substrate is bioactive glass granules of less than 1000µm in diameter.
12. The method of claim 1 wherein the substrate is porous.
13. The method of claim 12 wherein the substrate contains pores with diameter of less than about 850µm.
14. The method of claim 12 wherein the substrate has a percent density of less than about 80%.
15. A bioactive substrate comprising a porous polymer foam coated with sol gel bioactive material.
16. A bioactive substrate of claim 15 wherein the polymer foam is D,L poly(lactide-co-glycolide).
17. A bioactive substrate of claim 15 wherein the sol gel bioactive material is comprised of from about 60 to about 100% SiO2; up to about 40% CaO; and up to about 10% P2O5.
18. A bioactive substrate of claim 17 wherein the sol gel bioactive material has the nominal composition 70%
SiO2, 25% CaO, 5% P2O5.
SiO2, 25% CaO, 5% P2O5.
19. A bioactive substrate of claim 15 having a pore size of less than about 850 µm.
20. A bioactive substrate of claim 15 having a percent density less than about 80%.
21. A method of making a bioactive substrate comprising a porous polymer coated with sol gel bioactive material comprising the steps of:
coating a porous polymer with sol gel bioactive material; and evacuating residual sol gel bioactive material from the pores of the polymer.
coating a porous polymer with sol gel bioactive material; and evacuating residual sol gel bioactive material from the pores of the polymer.
22. The method of claim 21 wherein the pores of the polymer are evacuated by creating a suction vacuum.
23. The method of claim 21 wherein the polymer foam is D,L poly(lactide-co-glycolide).
24. The method of claim 21 wherein the sol gel bioactive material is comprised of from about 60 to about 100%
SiO2, up to about 40% CaO; and up to about 10% P2O5.
SiO2, up to about 40% CaO; and up to about 10% P2O5.
25. The method of claim 24 wherein the sol gel bioactive material has the nominal composition 70% SiO2, 25%
CaO, 5% P2O5.
CaO, 5% P2O5.
26. The method of claim 21 wherein the polymer foam has a pore size of less than about 850 µm.
27. The method of claim 21 wherein the polymer foam has a percent density of less than about 80%.
28. A method of preparing intervertebral disc cell culture comprising:
obtaining intervertebral disc tissue;
treating tissue with collagenase;
washing cells to remove collagenase; and incubating cells in a medium comprising hyaluronidase until cell attachment.
obtaining intervertebral disc tissue;
treating tissue with collagenase;
washing cells to remove collagenase; and incubating cells in a medium comprising hyaluronidase until cell attachment.
29. The method of claim 28 further comprising seeding cells on a biodegradable substrate.
The method of claim 28 further comprising replacing hyaluronidase medium with medium supplemented with ascorbic acid following cell attachment.
31. The method of claim 28 wherein the cells are incubated in 0.25% collagenase for 2 hours.
32. The method of claim 28 wherein the hyaluronidase medium comprises 1% hyaluronidase.
33. The method of claim 29 wherein the substrate is bioactive.
34. A hybrid material for reforming degenerated intervertebral disc tissue of a patient comprising a biodegradable substrate and intervertebral disc cells.
35. The hybrid material of claim 34 wherein the biodegradable substrate is bioactive.
36. The hybrid material of claim 34 shaped for surgical insertion into the intervertebral disc space.
37. The hybrid material of claim 34 wherein the biodegradable substrate is bioactive glass, polymer foam, or polymer foam coated with sol gel bioactive material.
38. The hybrid material of claim 37 wherein the polymer foam is the copolymer D,L poly(lactide-co-glycolide).
39. The hybrid material of claim 38 wherein the copolymer comprises 75% polylactide and 25% glycolide.
40. The hybrid material of claim 34 wherein the substrate is bioactive glass granules of less than 1000µm in diameter.
41. The hybrid material of claim 34 wherein the substrate contains pores with diameter of less than about 850µm.
42. The hybrid material of claim 33 wherein the substrate has a percent density of less than about 80%.
43. The hybrid material of claim 38 wherein the polymer foam is coated with a sol gel bioactive material comprised of from about 60 to about 100% SiO2, up to about 40%
CaO; and up to about 10% P2O5.
CaO; and up to about 10% P2O5.
44. The hybrid material of claim 39 wherein the polymer foam is coated with a sol gel bioactive material having a nominal composition of 70% SiO2, 25% CaO, 5% P2O5.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/694,191 | 1996-08-08 | ||
US08/694,191 US5964807A (en) | 1996-08-08 | 1996-08-08 | Compositions and methods for intervertebral disc reformation |
PCT/US1997/013854 WO1998005274A1 (en) | 1996-08-08 | 1997-08-06 | Compositions and methods for intervertebral disc reformation |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2262384A1 true CA2262384A1 (en) | 1998-02-12 |
Family
ID=24787795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002262384A Abandoned CA2262384A1 (en) | 1996-08-08 | 1997-08-06 | Compositions and methods for intervertebral disc reformation |
Country Status (6)
Country | Link |
---|---|
US (3) | US5964807A (en) |
EP (1) | EP0928173A4 (en) |
JP (1) | JP2002507899A (en) |
AU (1) | AU731019B2 (en) |
CA (1) | CA2262384A1 (en) |
WO (1) | WO1998005274A1 (en) |
Families Citing this family (202)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5964807A (en) | 1996-08-08 | 1999-10-12 | Trustees Of The University Of Pennsylvania | Compositions and methods for intervertebral disc reformation |
FI972890A (en) * | 1997-07-08 | 1999-01-09 | Bioxid Oy | New plastic-based composite and its use |
US6241771B1 (en) * | 1997-08-13 | 2001-06-05 | Cambridge Scientific, Inc. | Resorbable interbody spinal fusion devices |
EP0896825B1 (en) | 1997-08-14 | 2002-07-17 | Sulzer Innotec Ag | Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors |
US6080579A (en) * | 1997-11-26 | 2000-06-27 | Charlotte-Mecklenburg Hospital Authority | Method for producing human intervertebral disc cells |
DE19817698A1 (en) * | 1998-04-22 | 1999-10-28 | Jan Zoellner | Composition used for flat disk implant, especially nucleus pulposus implant |
SE9801495D0 (en) * | 1998-04-28 | 1998-04-28 | Astra Ab | Protein formulation |
US20040033950A1 (en) * | 2000-09-26 | 2004-02-19 | Hock Janet M. | Method of increasing bone toughness and stiffness and reducing fractures |
US6419704B1 (en) * | 1999-10-08 | 2002-07-16 | Bret Ferree | Artificial intervertebral disc replacement methods and apparatus |
US7201776B2 (en) * | 1999-10-08 | 2007-04-10 | Ferree Bret A | Artificial intervertebral disc replacements with endplates |
US20040249461A1 (en) * | 1999-08-13 | 2004-12-09 | Ferree Bret A. | Coupled artificial disc replacements methods and apparatus |
US6755863B2 (en) * | 1999-10-08 | 2004-06-29 | Bret A. Ferree | Rotator cuff repair using engineered tissues |
US7435260B2 (en) * | 1999-08-13 | 2008-10-14 | Ferree Bret A | Use of morphogenetic proteins to treat human disc disease |
US7717961B2 (en) * | 1999-08-18 | 2010-05-18 | Intrinsic Therapeutics, Inc. | Apparatus delivery in an intervertebral disc |
JP4247519B2 (en) * | 1999-08-18 | 2009-04-02 | イントリンジック セラピューティックス インコーポレイテッド | Apparatus and method for nucleus augmentation and retention |
US7972337B2 (en) | 2005-12-28 | 2011-07-05 | Intrinsic Therapeutics, Inc. | Devices and methods for bone anchoring |
US8323341B2 (en) | 2007-09-07 | 2012-12-04 | Intrinsic Therapeutics, Inc. | Impaction grafting for vertebral fusion |
EP1624832A4 (en) | 1999-08-18 | 2008-12-24 | Intrinsic Therapeutics Inc | Devices and method for augmenting a vertebral disc nucleus |
WO2009033100A1 (en) | 2007-09-07 | 2009-03-12 | Intrinsic Therapeutics, Inc. | Bone anchoring systems |
EP1210038A1 (en) | 1999-08-20 | 2002-06-05 | Peter Metz-Stavenhagen | Vertebral column segment |
US20030026788A1 (en) * | 1999-10-08 | 2003-02-06 | Ferree Bret A. | Use of extracellular matrix tissue to preserve cultured cell phenotype |
US20040172019A1 (en) * | 1999-10-08 | 2004-09-02 | Ferree Bret A. | Reinforcers for artificial disc replacement methods and apparatus |
US6648920B2 (en) * | 1999-10-08 | 2003-11-18 | Bret A. Ferree | Natural and synthetic supplements to engineered annulus and disc tissues |
US6645247B2 (en) * | 1999-10-08 | 2003-11-11 | Bret A. Ferree | Supplementing engineered annulus tissues with autograft of allograft tendons |
US7060100B2 (en) * | 1999-10-08 | 2006-06-13 | Ferree Bret A | Artificial disc and joint replacements with modular cushioning components |
US7201774B2 (en) * | 1999-10-08 | 2007-04-10 | Ferree Bret A | Artificial intervertebral disc replacements incorporating reinforced wall sections |
US7935147B2 (en) | 1999-10-20 | 2011-05-03 | Anulex Technologies, Inc. | Method and apparatus for enhanced delivery of treatment device to the intervertebral disc annulus |
US7615076B2 (en) | 1999-10-20 | 2009-11-10 | Anulex Technologies, Inc. | Method and apparatus for the treatment of the intervertebral disc annulus |
US7004970B2 (en) | 1999-10-20 | 2006-02-28 | Anulex Technologies, Inc. | Methods and devices for spinal disc annulus reconstruction and repair |
US20030153976A1 (en) | 1999-10-20 | 2003-08-14 | Cauthen Joseph C. | Spinal disc annulus reconstruction method and spinal disc annulus stent |
US7951201B2 (en) | 1999-10-20 | 2011-05-31 | Anulex Technologies, Inc. | Method and apparatus for the treatment of the intervertebral disc annulus |
US6592625B2 (en) | 1999-10-20 | 2003-07-15 | Anulex Technologies, Inc. | Spinal disc annulus reconstruction method and spinal disc annulus stent |
US8632590B2 (en) | 1999-10-20 | 2014-01-21 | Anulex Technologies, Inc. | Apparatus and methods for the treatment of the intervertebral disc |
WO2001028464A1 (en) | 1999-10-20 | 2001-04-26 | Anulex Technologies, Inc. | Spinal disc annulus reconstruction method and spinal disc annulus stent |
US7052516B2 (en) | 1999-10-20 | 2006-05-30 | Anulex Technologies, Inc. | Spinal disc annulus reconstruction method and deformable spinal disc annulus stent |
US8128698B2 (en) | 1999-10-20 | 2012-03-06 | Anulex Technologies, Inc. | Method and apparatus for the treatment of the intervertebral disc annulus |
EP1974698A3 (en) | 1999-10-20 | 2009-01-28 | Anulex Technologies, Inc. | Spinal disc annulus stent |
US6328990B1 (en) * | 1999-11-12 | 2001-12-11 | The Trustees Of The University Of Pennsylvania | Bioactive, degradable composite for tissue engineering |
DK1229940T3 (en) | 1999-11-15 | 2014-08-18 | Piramal Healthcare Canada Ltd | TEMPERATURE CONTROL AND PH-DEPENDENT SELF-GELING, Aqueous BIOPOLYMER SOLUTION |
US6432106B1 (en) * | 1999-11-24 | 2002-08-13 | Depuy Acromed, Inc. | Anterior lumbar interbody fusion cage with locking plate |
US6592624B1 (en) | 1999-11-24 | 2003-07-15 | Depuy Acromed, Inc. | Prosthetic implant element |
DK1244388T3 (en) * | 1999-12-06 | 2007-05-14 | Warsaw Orthopedic Inc | Device for treating intervertebral discs |
AU2001231264A1 (en) | 2000-01-31 | 2001-08-07 | Advanced Research And Technology Institute, Inc. | Composite biomaterial including anisometric calcium phosphate reinforcement particles and related methods |
US6899716B2 (en) * | 2000-02-16 | 2005-05-31 | Trans1, Inc. | Method and apparatus for spinal augmentation |
US7727263B2 (en) | 2000-02-16 | 2010-06-01 | Trans1, Inc. | Articulating spinal implant |
US6805695B2 (en) | 2000-04-04 | 2004-10-19 | Spinalabs, Llc | Devices and methods for annular repair of intervertebral discs |
US6723335B1 (en) * | 2000-04-07 | 2004-04-20 | Jeffrey William Moehlenbruck | Methods and compositions for treating intervertebral disc degeneration |
PT1294414E (en) | 2000-06-29 | 2006-07-31 | Biosyntech Canada Inc | COMPOSITION AND METHOD FOR THE REPAIR AND REGENERATION OF CARTILAGE AND OTHER FABRICS |
ATE466072T1 (en) * | 2000-06-29 | 2010-05-15 | Mount Sinai Hospital Corp | DISC |
CA2429168C (en) * | 2000-11-15 | 2010-06-08 | Bio Syntech Canada Inc. | Method for restoring a damaged or degenerated intervertebral disc |
US6890343B2 (en) | 2000-12-14 | 2005-05-10 | Ensure Medical, Inc. | Plug with detachable guidewire element and methods for use |
US8083768B2 (en) | 2000-12-14 | 2011-12-27 | Ensure Medical, Inc. | Vascular plug having composite construction |
US6623509B2 (en) | 2000-12-14 | 2003-09-23 | Core Medical, Inc. | Apparatus and methods for sealing vascular punctures |
US6846319B2 (en) | 2000-12-14 | 2005-01-25 | Core Medical, Inc. | Devices for sealing openings through tissue and apparatus and methods for delivering them |
US6896692B2 (en) | 2000-12-14 | 2005-05-24 | Ensure Medical, Inc. | Plug with collet and apparatus and method for delivering such plugs |
US20020114795A1 (en) | 2000-12-22 | 2002-08-22 | Thorne Kevin J. | Composition and process for bone growth and repair |
US20060127264A1 (en) * | 2001-02-01 | 2006-06-15 | Giovanni Aquino | Multi-vane device |
US20020115742A1 (en) * | 2001-02-22 | 2002-08-22 | Trieu Hai H. | Bioactive nanocomposites and methods for their use |
US20040083002A1 (en) * | 2001-04-06 | 2004-04-29 | Belef William Martin | Methods for treating spinal discs |
US20020147497A1 (en) | 2001-04-06 | 2002-10-10 | Integrated Vascular Systems, Inc. | Methods for treating spinal discs |
US20030069639A1 (en) * | 2001-04-14 | 2003-04-10 | Tom Sander | Methods and compositions for repair or replacement of joints and soft tissues |
WO2003002021A2 (en) * | 2001-06-29 | 2003-01-09 | The Regents Of The University Of California | Biodegradable/bioactive nucleus pulposus implant and method for treating degenerated intervertebral discs |
US20090234457A1 (en) * | 2001-06-29 | 2009-09-17 | The Regents Of The University Of California | Systems, devices and methods for treatment of intervertebral disorders |
US6736815B2 (en) * | 2001-09-06 | 2004-05-18 | Core Medical, Inc. | Apparatus and methods for treating spinal discs |
EP1429817B8 (en) * | 2001-09-24 | 2007-09-12 | Millenium Biologix Technologies Inc. | Porous ceramic composite bone grafts |
US20040010251A1 (en) * | 2001-12-10 | 2004-01-15 | Shahar Pitaru | Methods, devices, and preparations for intervertebral disc treatment |
SE0104323D0 (en) * | 2001-12-20 | 2001-12-20 | Matts Andersson | Method and arrangement of implants for preferably human intermediate disc and such implant |
US20030220692A1 (en) * | 2002-02-09 | 2003-11-27 | Shapiro Irving M. | Preparations of nucleus pulposus cells and methods for their generation, identification, and use |
AR038680A1 (en) | 2002-02-19 | 2005-01-26 | Synthes Ag | INTERVERTEBRAL IMPLANT |
US7001433B2 (en) | 2002-05-23 | 2006-02-21 | Pioneer Laboratories, Inc. | Artificial intervertebral disc device |
US8388684B2 (en) | 2002-05-23 | 2013-03-05 | Pioneer Signal Technology, Inc. | Artificial disc device |
US7622562B2 (en) | 2002-06-26 | 2009-11-24 | Zimmer Orthobiologics, Inc. | Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue |
US7066962B2 (en) * | 2002-07-23 | 2006-06-27 | Porex Surgical, Inc. | Composite surgical implant made from macroporous synthetic resin and bioglass particles |
US6958078B2 (en) * | 2002-08-19 | 2005-10-25 | The University Of Toledo | Bioartificial intervertebral disc |
CN1697634A (en) * | 2002-09-18 | 2005-11-16 | Sdgi控股股份有限公司 | Natural tissue devices and methods of implantation |
US7744651B2 (en) | 2002-09-18 | 2010-06-29 | Warsaw Orthopedic, Inc | Compositions and methods for treating intervertebral discs with collagen-based materials |
US20040054414A1 (en) * | 2002-09-18 | 2004-03-18 | Trieu Hai H. | Collagen-based materials and methods for augmenting intervertebral discs |
US7309359B2 (en) * | 2003-08-21 | 2007-12-18 | Warsaw Orthopedic, Inc. | Allogenic/xenogenic implants and methods for augmenting or repairing intervertebral discs |
US7273496B2 (en) * | 2002-10-29 | 2007-09-25 | St. Francis Medical Technologies, Inc. | Artificial vertebral disk replacement implant with crossbar spacer and method |
US7083649B2 (en) * | 2002-10-29 | 2006-08-01 | St. Francis Medical Technologies, Inc. | Artificial vertebral disk replacement implant with translating pivot point |
JP2006505331A (en) * | 2002-11-05 | 2006-02-16 | スパインオロジー,インク. | Semi-artificial intervertebral disc replacement system |
JP2006515765A (en) | 2002-11-15 | 2006-06-08 | エスディージーアイ・ホールディングス・インコーポレーテッド | Collagen-based materials and methods for treating synovial joints |
US20040186471A1 (en) * | 2002-12-07 | 2004-09-23 | Sdgi Holdings, Inc. | Method and apparatus for intervertebral disc expansion |
AU2004208821B2 (en) * | 2003-01-31 | 2009-01-15 | Zimmer Orthobiologics Inc. | Hydrogel compositions comprising nucleus pulposus tissue |
ES2393099T3 (en) | 2003-02-06 | 2012-12-18 | Synthes Gmbh | Intervertebral implant |
US7819903B2 (en) | 2003-03-31 | 2010-10-26 | Depuy Spine, Inc. | Spinal fixation plate |
US7112222B2 (en) * | 2003-03-31 | 2006-09-26 | Depuy Spine, Inc. | Anterior lumbar interbody fusion cage with locking plate |
US7067169B2 (en) * | 2003-06-04 | 2006-06-27 | Chemat Technology Inc. | Coated implants and methods of coating |
US20040244806A1 (en) * | 2003-06-09 | 2004-12-09 | Ferree Bret A. | Treating disc herniation and other conditions with leukocytes |
US7909869B2 (en) * | 2003-08-05 | 2011-03-22 | Flexuspine, Inc. | Artificial spinal unit assemblies |
US7316714B2 (en) * | 2003-08-05 | 2008-01-08 | Flexuspine, Inc. | Artificial functional spinal unit assemblies |
US7204853B2 (en) * | 2003-08-05 | 2007-04-17 | Flexuspine, Inc. | Artificial functional spinal unit assemblies |
US7753958B2 (en) * | 2003-08-05 | 2010-07-13 | Gordon Charles R | Expandable intervertebral implant |
US8603168B2 (en) | 2003-08-05 | 2013-12-10 | Flexuspine, Inc. | Artificial functional spinal unit system and method for use |
US7822983B2 (en) | 2003-08-21 | 2010-10-26 | Microsoft Corporation | Physical device bonding |
US7632294B2 (en) * | 2003-09-29 | 2009-12-15 | Promethean Surgical Devices, Llc | Devices and methods for spine repair |
US20050071012A1 (en) * | 2003-09-30 | 2005-03-31 | Hassan Serhan | Methods and devices to replace spinal disc nucleus pulposus |
US7879102B2 (en) * | 2003-09-30 | 2011-02-01 | Depuy Acromed, Inc. | Method for treatment of defects in the intervertebral disc |
US7655012B2 (en) | 2003-10-02 | 2010-02-02 | Zimmer Spine, Inc. | Methods and apparatuses for minimally invasive replacement of intervertebral discs |
US20050090899A1 (en) * | 2003-10-24 | 2005-04-28 | Dipoto Gene | Methods and apparatuses for treating the spine through an access device |
US7041137B2 (en) * | 2003-10-07 | 2006-05-09 | Lanx, Llc | Spinal implant |
US8852229B2 (en) | 2003-10-17 | 2014-10-07 | Cordis Corporation | Locator and closure device and method of use |
US7361183B2 (en) | 2003-10-17 | 2008-04-22 | Ensure Medical, Inc. | Locator and delivery device and method of use |
CA2543295A1 (en) | 2003-10-23 | 2005-05-06 | Trans1 Inc. | Tools and tool kits for performing minimally invasive procedures on the spine |
WO2005041987A1 (en) * | 2003-10-29 | 2005-05-12 | Gentis, Inc. | Polymerizable emulsions for tissue engineering |
US7691146B2 (en) | 2003-11-21 | 2010-04-06 | Kyphon Sarl | Method of laterally inserting an artificial vertebral disk replacement implant with curved spacer |
US7217291B2 (en) | 2003-12-08 | 2007-05-15 | St. Francis Medical Technologies, Inc. | System and method for replacing degenerated spinal disks |
US20050209602A1 (en) * | 2004-03-22 | 2005-09-22 | Disc Dynamics, Inc. | Multi-stage biomaterial injection system for spinal implants |
US20050273172A1 (en) * | 2004-06-07 | 2005-12-08 | Patil Arun A | Artificial disc and uses therefor |
US8697139B2 (en) | 2004-09-21 | 2014-04-15 | Frank M. Phillips | Method of intervertebral disc treatment using articular chondrocyte cells |
US20060153384A1 (en) * | 2004-12-30 | 2006-07-13 | Microsoft Corporation | Extensible architecture for untrusted medium device configuration via trusted medium |
US7879103B2 (en) * | 2005-04-15 | 2011-02-01 | Musculoskeletal Transplant Foundation | Vertebral disc repair |
WO2006115805A2 (en) | 2005-04-27 | 2006-11-02 | The Trustees Of The University Of Pennsylvania | Xerogel films for the controlled release of pharmaceutically active molecules |
US8926654B2 (en) | 2005-05-04 | 2015-01-06 | Cordis Corporation | Locator and closure device and method of use |
US8088144B2 (en) | 2005-05-04 | 2012-01-03 | Ensure Medical, Inc. | Locator and closure device and method of use |
US7657255B2 (en) | 2005-06-23 | 2010-02-02 | Microsoft Corporation | Provisioning of wireless connectivity for devices using NFC |
US20070010815A1 (en) * | 2005-06-30 | 2007-01-11 | Sdgi Holdings, Inc. | Fixation systems with modulated stiffness |
US20070027543A1 (en) * | 2005-08-01 | 2007-02-01 | Gimble Jeffrey M | Use of adipose tissue-derived stromal cells in spinal fusion |
AU2006281242A1 (en) * | 2005-08-19 | 2007-02-22 | Astrazeneca Ab | Pyrazolone derivatives for the treatment of tuberculosis |
US20070083210A1 (en) * | 2005-09-16 | 2007-04-12 | Zimmer Spine, Inc. | Apparatus and method for minimally invasive spine surgery |
EP1767161A1 (en) * | 2005-09-22 | 2007-03-28 | Zimmer Spine, Inc. | Spinal fixation rod contouring system |
US10105207B2 (en) * | 2005-10-25 | 2018-10-23 | Globus Medical, Inc. | Porous and nonporous materials for tissue grafting and repair |
US8029575B2 (en) * | 2005-10-25 | 2011-10-04 | Globus Medical, Inc. | Porous and nonporous materials for tissue grafting and repair |
US20070093906A1 (en) * | 2005-10-26 | 2007-04-26 | Zimmer Spine, Inc. | Nucleus implant and method |
WO2007059038A2 (en) | 2005-11-14 | 2007-05-24 | Biomet 3I, Inc. | Deposition of discrete nanoparticles on an implant surface |
US20070150063A1 (en) * | 2005-12-22 | 2007-06-28 | Depuy Spine, Inc. | Devices for intervertebral augmentation and methods of controlling their delivery |
US20070150064A1 (en) * | 2005-12-22 | 2007-06-28 | Depuy Spine, Inc. | Methods and devices for intervertebral augmentation |
US20070150059A1 (en) * | 2005-12-22 | 2007-06-28 | Depuy Spine, Inc. | Methods and devices for intervertebral augmentation using injectable formulations and enclosures |
US20070179618A1 (en) * | 2006-01-31 | 2007-08-02 | Sdgi Holdings, Inc. | Intervertebral prosthetic disc |
US20100305704A1 (en) | 2006-02-27 | 2010-12-02 | Synthes Gmbh | Intervertebral implant with fixation geometry |
US8118869B2 (en) | 2006-03-08 | 2012-02-21 | Flexuspine, Inc. | Dynamic interbody device |
US20070254038A1 (en) * | 2006-04-26 | 2007-11-01 | The Trustees Of The University Of Pennsylvania | Microspheroidal Controlled Release Of Biomolecules |
WO2008078157A2 (en) * | 2006-04-28 | 2008-07-03 | The University Of Hong Kong | Bioengineered intervertebral discs and methods for their preparation |
KR100738476B1 (en) * | 2006-05-08 | 2007-07-11 | 주식회사 제노스 | Membrane for guided bone regerneration and preparation method thereof |
US8118779B2 (en) | 2006-06-30 | 2012-02-21 | Warsaw Orthopedic, Inc. | Collagen delivery device |
US8399619B2 (en) | 2006-06-30 | 2013-03-19 | Warsaw Orthopedic, Inc. | Injectable collagen material |
US20080004703A1 (en) * | 2006-06-30 | 2008-01-03 | Warsaw Orthopedic, Inc. | Method of treating a patient using a collagen material |
US20080004431A1 (en) * | 2006-06-30 | 2008-01-03 | Warsaw Orthopedic Inc | Method of manufacturing an injectable collagen material |
US20080014179A1 (en) * | 2006-07-11 | 2008-01-17 | Ferree Bret A | Tissue transplantation compositions and methods |
CA2658934A1 (en) * | 2006-07-25 | 2008-01-31 | Musculoskeletal Transplant Foundation | Packed demineralized cancellous tissue forms for disc nucleus augmentation, restoration, or replacement and methods of implantation |
US20080026032A1 (en) * | 2006-07-27 | 2008-01-31 | Zubery Yuval | Composite implants for promoting bone regeneration and augmentation and methods for their preparation and use |
EP2063817A4 (en) | 2006-09-15 | 2012-04-18 | Pioneer Surgical Technology Inc | Joint arthroplasty devices having articulating members |
US8715350B2 (en) | 2006-09-15 | 2014-05-06 | Pioneer Surgical Technology, Inc. | Systems and methods for securing an implant in intervertebral space |
US20080082170A1 (en) * | 2006-09-29 | 2008-04-03 | Peterman Marc M | Apparatus and methods for surgical repair |
US8323642B2 (en) * | 2006-12-13 | 2012-12-04 | Depuy Mitek, Inc. | Tissue fusion method using collagenase for repair of soft tissue |
US7905922B2 (en) | 2006-12-20 | 2011-03-15 | Zimmer Spine, Inc. | Surgical implant suitable for replacement of an intervertebral disc |
US7718616B2 (en) | 2006-12-21 | 2010-05-18 | Zimmer Orthobiologics, Inc. | Bone growth particles and osteoinductive composition thereof |
US8940022B2 (en) | 2007-01-19 | 2015-01-27 | Flexuspine, Inc. | Artificial functional spinal unit system and method for use |
WO2008109695A2 (en) * | 2007-03-06 | 2008-09-12 | Orthobond, Inc. | Preparation tools and methods of using the same |
US7648521B2 (en) * | 2007-03-15 | 2010-01-19 | Zimmer Spine, Inc. | System and method for minimally invasive spinal surgery |
US20080288074A1 (en) * | 2007-05-15 | 2008-11-20 | O'neil Michael J | Internally reinforced elastomeric intervertebral disc implants |
CN101802175B (en) | 2007-07-12 | 2014-03-12 | 迪斯克基因公司 | Human disc tissue |
US8157844B2 (en) | 2007-10-22 | 2012-04-17 | Flexuspine, Inc. | Dampener system for a posterior stabilization system with a variable length elongated member |
US8162994B2 (en) | 2007-10-22 | 2012-04-24 | Flexuspine, Inc. | Posterior stabilization system with isolated, dual dampener systems |
US8523912B2 (en) | 2007-10-22 | 2013-09-03 | Flexuspine, Inc. | Posterior stabilization systems with shared, dual dampener systems |
US8182514B2 (en) | 2007-10-22 | 2012-05-22 | Flexuspine, Inc. | Dampener system for a posterior stabilization system with a fixed length elongated member |
US8267965B2 (en) | 2007-10-22 | 2012-09-18 | Flexuspine, Inc. | Spinal stabilization systems with dynamic interbody devices |
US8187330B2 (en) | 2007-10-22 | 2012-05-29 | Flexuspine, Inc. | Dampener system for a posterior stabilization system with a variable length elongated member |
WO2009064644A1 (en) | 2007-11-16 | 2009-05-22 | Synthes(U.S.A.) | Low profile intervertebral implant |
ES2545781T3 (en) | 2008-01-28 | 2015-09-15 | Biomet 3I, Llc | Superficial implant with greater hydrophilicity |
US20090324695A1 (en) * | 2008-05-30 | 2009-12-31 | Paul Ducheyne | Biocompatible polymer ceramic composite matrices |
DE102008032027A1 (en) * | 2008-07-07 | 2010-01-21 | Schaeffler Kg | Bearing arrangement for use with device, has two-row roller bearing, where two rows of rollers are arranged in circumferential direction around rotation axis |
US8814937B2 (en) | 2008-09-18 | 2014-08-26 | Peter L. Mayer | Intervertebral disc prosthesis, method for assembling, method for implanting prosthesis, and method for explanting |
US8187333B2 (en) * | 2008-09-18 | 2012-05-29 | Mayer Peter L | Intervertebral disc prosthesis and method for implanting and explanting |
US8163022B2 (en) | 2008-10-14 | 2012-04-24 | Anulex Technologies, Inc. | Method and apparatus for the treatment of the intervertebral disc annulus |
RU2506930C2 (en) | 2008-11-07 | 2014-02-20 | Зинтес Гмбх | Intervertebral insert and coupled plate assembly |
WO2010107692A1 (en) | 2009-03-16 | 2010-09-23 | Synthes Usa, Llc | System and method for stabilizing vertebrae in spine surgery through a lateral access channel |
US9775721B2 (en) | 2009-07-10 | 2017-10-03 | Bio2 Technologies, Inc. | Resorbable interbody device |
US9028553B2 (en) | 2009-11-05 | 2015-05-12 | DePuy Synthes Products, Inc. | Self-pivoting spinal implant and associated instrumentation |
US8460319B2 (en) | 2010-01-11 | 2013-06-11 | Anulex Technologies, Inc. | Intervertebral disc annulus repair system and method |
CN102188749A (en) * | 2010-03-10 | 2011-09-21 | 中国科学院上海硅酸盐研究所 | 3D porous bracket with mesoporous biological glass coating and preparation method thereof |
US8641418B2 (en) | 2010-03-29 | 2014-02-04 | Biomet 3I, Llc | Titanium nano-scale etching on an implant surface |
US8353964B2 (en) | 2010-11-04 | 2013-01-15 | Carpenter Clyde T | Anatomic total disc replacement |
CA2817584C (en) | 2010-11-15 | 2018-01-02 | Zimmer Orthobiologics, Inc. | Bone void fillers |
EP2654626B1 (en) | 2010-12-21 | 2016-02-24 | Synthes GmbH | Intervertebral implants and systems |
US8388687B2 (en) | 2011-03-25 | 2013-03-05 | Flexuspine, Inc. | Interbody device insertion systems and methods |
US9526627B2 (en) | 2011-11-17 | 2016-12-27 | Exactech, Inc. | Expandable interbody device system and method |
US9198769B2 (en) | 2011-12-23 | 2015-12-01 | Pioneer Surgical Technology, Inc. | Bone anchor assembly, bone plate system, and method |
ES2671740T3 (en) | 2012-03-20 | 2018-06-08 | Biomet 3I, Llc | Treatment surface for an implant surface |
US9393126B2 (en) | 2012-04-20 | 2016-07-19 | Peter L. Mayer | Bilaterally placed disc prosthesis for spinal implant and method of bilateral placement |
US9364339B2 (en) | 2012-04-30 | 2016-06-14 | Peter L. Mayer | Unilaterally placed expansile spinal prosthesis |
US10022245B2 (en) | 2012-12-17 | 2018-07-17 | DePuy Synthes Products, Inc. | Polyaxial articulating instrument |
US9737294B2 (en) | 2013-01-28 | 2017-08-22 | Cartiva, Inc. | Method and system for orthopedic repair |
WO2014117107A1 (en) | 2013-01-28 | 2014-07-31 | Cartiva, Inc. | Systems and methods for orthopedic repair |
US9492288B2 (en) | 2013-02-20 | 2016-11-15 | Flexuspine, Inc. | Expandable fusion device for positioning between adjacent vertebral bodies |
US9913728B2 (en) | 2013-03-14 | 2018-03-13 | Quandary Medical, Llc | Spinal implants and implantation system |
WO2015017324A1 (en) * | 2013-08-02 | 2015-02-05 | Bi02 Technologies, Inc. | Resorbable interbody device |
US20150265745A1 (en) * | 2014-03-18 | 2015-09-24 | Globus Medical, Inc | Porous and Nonporous Materials for Tissue Grafting and Repair |
US9517144B2 (en) | 2014-04-24 | 2016-12-13 | Exactech, Inc. | Limited profile intervertebral implant with incorporated fastening mechanism |
US10398565B2 (en) | 2014-04-24 | 2019-09-03 | Choice Spine, Llc | Limited profile intervertebral implant with incorporated fastening and locking mechanism |
US9867718B2 (en) | 2014-10-22 | 2018-01-16 | DePuy Synthes Products, Inc. | Intervertebral implants, systems, and methods of use |
US10136958B2 (en) | 2014-10-28 | 2018-11-27 | Amendia, Inc. | Tissue protector and method of use |
US10195305B2 (en) | 2015-03-24 | 2019-02-05 | Orthovita, Inc. | Bioactive flowable wash-out resistant bone graft material and method for production thereof |
US10449055B2 (en) | 2015-04-23 | 2019-10-22 | Disc Fix L.L.C. | Systems and methods for treatment of intervertebral disc derangements |
EP3288500B1 (en) * | 2015-04-27 | 2021-09-29 | Corenman, Donald, Steven | Biological disc graft and method for relief of lower back pain and joint pain |
US10645921B2 (en) | 2016-12-20 | 2020-05-12 | Vivex Biologics Group, Inc. | Viable disc regenerative composition and method of manufacture and use |
US10966843B2 (en) | 2017-07-18 | 2021-04-06 | DePuy Synthes Products, Inc. | Implant inserters and related methods |
US11045331B2 (en) | 2017-08-14 | 2021-06-29 | DePuy Synthes Products, Inc. | Intervertebral implant inserters and related methods |
JP2020533070A (en) | 2017-09-08 | 2020-11-19 | パイオニア サージカル テクノロジー インコーポレイテッド | Intervertebral implants, instruments, and methods |
USD907771S1 (en) | 2017-10-09 | 2021-01-12 | Pioneer Surgical Technology, Inc. | Intervertebral implant |
US11285177B2 (en) | 2018-01-03 | 2022-03-29 | Globus Medical, Inc. | Allografts containing viable cells and methods thereof |
US11693423B2 (en) * | 2018-12-19 | 2023-07-04 | Waymo Llc | Model for excluding vehicle from sensor field of view |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4655777A (en) * | 1983-12-19 | 1987-04-07 | Southern Research Institute | Method of producing biodegradable prosthesis and products therefrom |
US5133755A (en) * | 1986-01-28 | 1992-07-28 | Thm Biomedical, Inc. | Method and apparatus for diodegradable, osteogenic, bone graft substitute device |
FI80605C (en) * | 1986-11-03 | 1990-07-10 | Biocon Oy | Bone surgical biocomposite material |
US5041138A (en) * | 1986-11-20 | 1991-08-20 | Massachusetts Institute Of Technology | Neomorphogenesis of cartilage in vivo from cell culture |
US5108438A (en) * | 1989-03-02 | 1992-04-28 | Regen Corporation | Prosthetic intervertebral disc |
US5258043A (en) * | 1987-07-20 | 1993-11-02 | Regen Corporation | Method for making a prosthetic intervertebral disc |
US4772287A (en) * | 1987-08-20 | 1988-09-20 | Cedar Surgical, Inc. | Prosthetic disc and method of implanting |
FR2623402B1 (en) * | 1987-11-19 | 1994-04-29 | Solvay | ARTICLE OF LACTIC ACID POLYMER FOR USE IN PARTICULAR AS A BIODEGRADABLE PROSTHESIS AND METHOD FOR THE PRODUCTION THEREOF |
US4904206A (en) | 1988-04-12 | 1990-02-27 | Amp Incorporated | High voltage coaxial connector |
US5290552A (en) * | 1988-05-02 | 1994-03-01 | Matrix Pharmaceutical, Inc./Project Hear | Surgical adhesive material |
DE8807485U1 (en) * | 1988-06-06 | 1989-08-10 | Mecron Medizinische Produkte Gmbh, 1000 Berlin, De | |
US4911718A (en) * | 1988-06-10 | 1990-03-27 | University Of Medicine & Dentistry Of N.J. | Functional and biocompatible intervertebral disc spacer |
FR2646084B1 (en) * | 1989-04-20 | 1994-09-16 | Fbfc International Sa | BIOREACTIVE MATERIAL FOR FILLING BONE CAVITES |
US5376118A (en) * | 1989-05-10 | 1994-12-27 | United States Surgical Corporation | Support material for cell impregnation |
US5035713A (en) * | 1990-02-12 | 1991-07-30 | Orthopaedic Research Institute, Inc. | Surgical implants incorporating re-entrant material |
US5074916A (en) * | 1990-05-18 | 1991-12-24 | Geltech, Inc. | Alkali-free bioactive sol-gel compositions |
US5204104A (en) * | 1991-10-07 | 1993-04-20 | Pre Pak Products | Physical therapy massage stick and process |
US5263991A (en) * | 1992-10-21 | 1993-11-23 | Biomet, Inc. | Method for heating biocompatible implants in a thermal packaging line |
US5478739A (en) * | 1992-10-23 | 1995-12-26 | Advanced Tissue Sciences, Inc. | Three-dimensional stromal cell and tissue culture system |
US5290522A (en) | 1993-01-07 | 1994-03-01 | Minnesota Mining And Manufacturing Company | Catalytic converter mounting mat |
EP0713364A4 (en) * | 1993-08-13 | 1996-12-27 | Shalaby W Shalaby | Microporous polymeric foams and microtextured surfaces |
US5458642A (en) * | 1994-01-18 | 1995-10-17 | Beer; John C. | Synthetic intervertebral disc |
US5686091A (en) * | 1994-03-28 | 1997-11-11 | The Johns Hopkins University School Of Medicine | Biodegradable foams for cell transplantation |
US5591453A (en) * | 1994-07-27 | 1997-01-07 | The Trustees Of The University Of Pennsylvania | Incorporation of biologically active molecules into bioactive glasses |
US5964807A (en) | 1996-08-08 | 1999-10-12 | Trustees Of The University Of Pennsylvania | Compositions and methods for intervertebral disc reformation |
-
1996
- 1996-08-08 US US08/694,191 patent/US5964807A/en not_active Expired - Lifetime
-
1997
- 1997-08-06 JP JP50820198A patent/JP2002507899A/en active Pending
- 1997-08-06 CA CA002262384A patent/CA2262384A1/en not_active Abandoned
- 1997-08-06 AU AU39103/97A patent/AU731019B2/en not_active Ceased
- 1997-08-06 WO PCT/US1997/013854 patent/WO1998005274A1/en not_active Application Discontinuation
- 1997-08-06 EP EP97936433A patent/EP0928173A4/en not_active Withdrawn
-
1999
- 1999-05-19 US US09/314,511 patent/US6240926B1/en not_active Expired - Lifetime
-
2001
- 2001-04-12 US US09/833,284 patent/US6569442B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2002507899A (en) | 2002-03-12 |
US6569442B2 (en) | 2003-05-27 |
US20010020476A1 (en) | 2001-09-13 |
US6240926B1 (en) | 2001-06-05 |
AU3910397A (en) | 1998-02-25 |
US5964807A (en) | 1999-10-12 |
AU731019B2 (en) | 2001-03-22 |
WO1998005274A1 (en) | 1998-02-12 |
EP0928173A4 (en) | 2001-09-19 |
EP0928173A1 (en) | 1999-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6240926B1 (en) | Compositions and methods for intervertebral disc reformation | |
US11207187B2 (en) | In-situ formed intervertebral fusion device and method | |
AU758844B2 (en) | Compositions useful in intervertebral disc reformation | |
US11207189B2 (en) | Biological disc graft and method for relief of lower back pain and joint pain | |
KR100744833B1 (en) | Artificial intervertebral disc comprising disc cell and the method of tissue engineered disc regeneration using the said disc cell | |
WO2021015887A1 (en) | Biological disc graft and method for relief of lower back pain and joint pain | |
Goel et al. | Materials in Spine Surgery | |
Grant et al. | In-vivo usage of biomaterials: a snapshot of current activity. | |
Gan | Tissue engineering for intervertebral disc repair |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |